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ASTROCYTES MODULATE MICROGLIAL PHENOTYPE 
AND DENDRITIC CELL-LIKE PROPERTIES 
 
by 
Nischal K. Padala 
 
Microglia are the resident immune cells of the CNS. In the healthy CNS, they express 
negligible levels of MHC II molecules as well as co-stimulatory molecules CD40, CD80 
and CD86 necessary for antigen presentation to and activation of T cells. Co-stimulatory 
molecule expression can be induced in isolated microglia in vitro by sequential treatment 
with granulocyte monocyte colony-stimulating factor (GM-CSF) followed by 
lipopolysaccharide (LPS). Upon such treatment, they become mature dendritic cells 
(DCs), capable of activating T cells. However, microglia are not isolated in life, but 
rather exist in an environment enriched by other cells, notably astrocytes.   
Therefore, to determine the effect of astrocytes on the assumption by microglia of 
the DC phenotype, microglia  were treated with GM-CSF and LPS either in the presence 
or absence of astrocytes and assayed for the DC phenotypic marker CD11c and the co-
stimulatory CD40, CD80, CD86 and MHC II by flow cytometry. When compared to 
isolated microglia, a significantly lower percentage of microglia co-cultured with 
astrocytes expressed these markers. Astrocytes also prevent the expression of these 
molecules in bone marrow-derived DCs. Neither interleukin-10, transforming growth 
factor-beta, nor prostaglandin E2 are responsible for the inhibition. Rather, contact with 
the astrocytic environment is responsible for the suppressive qualities. 
 Microglia cultured in the presence of astrocytes are also functionally distinct from 





proliferation more robustly than do microglia in isolation. By contrast, a significantly 
higher percentage of CD4
+
 T cells stimulated with αCD3 in the presence of isolated 
microglia acquire an anti-inflammatory Foxp3
+
 T regulatory phenotype when compared 
to T cells cultured with microglia in the presence of astrocytes. This is not due to 
interactions between CD80/CD86 and CTLA4. The elevated presence of Foxp3
+
 T cells 
appears to be responsible for the lower level of T cell proliferation in the presence of 
isolated microglia. Finally, analysis of the supernatants from the T cell co-culture 
experiments reveal that astrocytic interaction(s) with microglia suppress T cell production 
of pro-inflammatory cytokines interferon-γ and interleukin-17. These data taken together 
suggest that astrocytes play a crucial role in modulating the microglial immune response 
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RATIONALE AND SPECIFIC AIMS 
1.1 Rationale 
Microglia – like other monocytically-derived cells – are capable of expressing a dendritic 
cell (DC) phenotype. When isolated in culture and properly stimulated, microglia 
produce major histocompatibility complex class II (MHC Class II) as well as the co-
stimulatory molecules CD40, CD80 and CD86 that allow them to present antigen and 
activate T cells. The production of an appropriate T cell response is of vital importance to 
the healthy brain, and understanding the role of microglia in regulating this T cell 
response is crucial. During multiple sclerosis (MS) or its animal model experimental 
autoimmune encephalomyelitis (EAE), pro-inflammatory myelin-specific T cells invade 
the brain parenchyma destroying the myelin sheath. On the other hand, glial tumors 
suppress T cell responses. While these tumors contain resident microglia, they are 
immune incompetent, unable to mount an attack against the tumor. Their immaturity with 
respect to antigen-presentation may contribute to an environment in which anti-
inflammatory Foxp3
+
 T regulatory cells are able to invade tumors and protect them 
against autoimmunity. The abundance of these regulatory cells is correlated with poor 
prognosis.  
The interaction between both normal and malignant astrocytes and microglia is an 
essential one. Nevertheless, studies revealing the antigen-presenting capabilities of 
microglia almost exclusively been performed in the absence of astrocytes. Thus, how 




this thesis will indicate how important it is to understand this interaction for a complete 
understanding of microglial biology.  
This thesis investigates the nature of an astrocytic/microglial cross-talk that 
affects the ability of microglia to assume a dendritic cell-like phenotype. Furthermore, the 
ability of microglia cultured in the presence or absence of astrocytes to influence CD4
+
 T 
cell proliferation and Foxp3 T cell differentiation is also examined. These studies address 
several specific aims, outlined below. 
1.2 Specific Aims 
Specific Aim 1. To determine whether the presence of astrocytes affects the ability of 
microglia to express dendritic cell (DC) markers CD11c, MHC Class II and co-
stimulatory molecules CD40, CD80 and CD86.  
Specific Aim 2. To determine whether differences in surface expression of these DC-
specific molecules is the result of soluble or contact-mediated events. 
Specific Aim 3. To examine the effects of differences in surface expression of these DC-







INTRODUCTION AND BACKGROUND 
2.1 Microglia 
The CNS comprises two major cell types: neurons and glial cells. The glial cells include 
microglia, astrocytes and oligodendrocytes (He and Sun, 2007). Microglia are the 
resident immune cells of the CNS and are derived from CD45
+
 myeloid precursors. The 
same lineage also gives rise to bone marrow-derived dendritic cells and granulocytes 
(Aloisi, 2001; Barron, 1995; Chan et al., 2007; Gehrmann et al., 1995; Kaur et al., 2001; 
Rezaie and Male, 2002). Microglia represent up to 20% of the total glial population in a 
healthy brain (Barron, 1995). It is generally accepted that microglial precursors migrate 
into the developing CNS from blood-producing centers during the mid-to-late embryonic 
and early postnatal periods (Kaur et al., 2001). There are two types of microglia in the 
CNS: perivascular and parenchymal. As their names suggest, perivascular microglia are 
found surrounding the vasculature of the CNS whereas parenchymal microglia are 
distributed throughout the brain and spinal cord (Barron, 1995; Chan et al., 2007; Kaur et 
al., 2001; Ling et al., 2001; Streit et al., 1988). Bone marrow chimera studies indicate that 
the perivascular population of microglia is slowly yet constantly replaced throughout life 
by bone marrow-derived precursors, whereas the parenchymal population is not (Simard 
and Rivest, 2004).  
  Microglia are among the first responders to CNS insults such as ischemia, trauma, 
and neurodegeneration (Aloisi, 1999; Glezer et al., 2007; Hickey, 2001; Kreutzberg, 
1996; Minghetti and Levi, 1998; Nakamura, 2002; Rock et al., 2004; Streit et al., 1999; 




factor (BDNF), nerve growth factor (NGF) and anti-inflammatory cytokines can 
influence the survival and regeneration of neural tissue after injury. On the other hand, 
microglial secretion of nitric oxide (NO), hydrogen peroxide (H2O2), and pro-
inflammatory cytokines can be neurotoxic (Banati et al., 1993; Minghetti and Levi, 1998; 
Stoll and Jander, 1999; Wu et al., 2009). The composition of microglial products seems 
to be determined by the nature and potency of the activating signals. 
In the normal brain microglia exhibit a ramified morphology, and, in the absence 
of an activation signal, exist in an “immature” phenotype (Nakamura, 2002; Ponomarev 
et al., 2005). Though un-activated, microglia constantly survey their microenvironment. 
Nimmerjahn and co-workers established that microglia in vivo are “highly dynamic 
surveillants of brain parenchyma.” They further reported that microglia appear to 
“sample” their neighboring parenchyma by rapidly extending and retracting their 
processes. In fact, this process is fast enough for the population of microglia to survey the 
entire CNS parenchyma within a few hours (Nimmerjahn et al., 2005). 
Microglia express or can be induced to express a wide variety of cell surface 
receptors that can detect the consequences of almost any CNS insult as illustrated in 
Table 2.1. Prominent among these are receptors for phagocytosis, chemotaxis, pathogen 
associated molecular patterns (PAMPs) and stress-related heat shock proteins (Olson and 
Miller, 2004; Raivich et al., 1993; Ransohoff et al., 2007). Microglial phagocytic activity 
is critical for removing debris resulting from apoptotic or necrotic cells in the CNS. The 
timely removal of apoptotic cells is of great importance as it prevents potentially 




of a cell that ultimately results in the phagocytosis of the apoptotic cell by macrophages 
or by microglia in the CNS. 
The expression of chemotactic receptors facilitates the migration of microglia to 
sites of injury within the CNS. Besides accumulating locally at the site of injury, 
chemokines released by activated microglia can further recruit infiltrating T cells, DCs, 
and macrophages (Cardona et al., 2008; Ransohoff et al., 2007; Rebenko-Moll et al., 
2006). Befitting their role as “CNS resident immune cells,” microglia activated by 
PAMPs can secrete numerous immunomodulatory compounds. Upon activation 
microglia in vitro can assume a dendritic cell-like phenotype characterized by high 
expression of CD40, CD80, CD86, MHC Class II and the capacity to stimulate T cell 
activation (Aloisi et al., 2000; Matyszak et al., 1999; Ponomarev et al., 2005; Ponomarev 
et al., 2006; Ponomarev et al., 2007).  Moreover, activated microglia can produce 
cytokines including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), IL-3, IL-5, 
IL-6, IL-10, IL-12, transforming growth factor beta (TGF-β) and the prostanoid 
prostaglandin E2 (PGE2) all of which can modulate the T cell response (Aloisi et al., 
1997; Aloisi et al., 1999; Aloisi, 2001; Banati et al., 1993; Mizuno et al., 1994b; Mizuno 

















Table 2.1  Molecular Signals and Modulators of Microglial Activation 
Class of Compound Examples 
Surface structures of infectious 
agents 
Lipopolysaccharide (LPS), 
bacterial cell wall proteoglycans, 
teichoic acid, gp41, gp120 
Abnormal endogenous proteins -amyloid, prion protein 
Complement Complement factor Clq, C5a 
Antibodies Immunoglogulin A (IgA), IgG, 
IgM 
Cytokines Interleukin-1  (IL-1 ), IL6, IL-10, 
IL-12, interferon-gamma (IFN ), 
TGF , TNF  
Chemokines (ligands for the 
chemokine receptors) 
CCR3, CCR5, CXCR2, CXCR4 
Neurotrophic factors Brain-derived neuronotrophic 
factor (BDNF0, glial cell line-
derived neuronotrophic factor 
(GDNF) 
Serum factors and proteases Albumin, thrombin 
Other proteins and peptides Apolipoprotein E, CD40L, 
vasoactive intestinal peptide (VIP) 
Neurotransmission-related 
compounds 







Other compounds Cannabinoids, ceramide, 
gangliosides, melatonin, platelet-
activating factor, PGE2 
Source: Adapted from van Rossum, D. and Hanisch, U.-K. (2004), Metabolic Brain 
Disease, 19:399 
 
By being immunocompetent microglia may play a role in the induction and 
etiology of autoimmune disorders such as multiple sclerosis (MS) (Becher et al., 2000b; 
Lubetzki et al., 2005; McQuaid et al., 2009; Ponomarev et al., 2005). The role of 
microglia in MS has come under intense scrutiny over the years, and yet the precise 




characterized by the loss of the myelin sheath surrounding axons. Most of the extant 
knowledge about MS pathology comes from studies using the animal model of 
experimental autoimmune encephelomyelities (EAE). EAE can be induced in rodents by 
immunization with myelin basic protein (MBP) or proteolipoprotein (PLP) or myelin 
oligodendrocyte glycoprotein (MOG) in complete Freund’s adjuvant (McMahon et al., 
2005). Although the precise cause of MS is not presently known, it is obvious that CD4
+
 
T cells specific for myelin-derived antigens are responsible for the progression of MS 
(Adamus et al., 1996; Aggarwal et al., 2003; Bailey et al., 2007; Becher et al., 2000a). It 
is important to note that naïve T cells specific for myelin-derived antigens exist in most 
people;     however, they only cause disease in a relatively small number of people. 
Several theories have been put forth to explain this apparent anomaly. The theory of 
molecular mimicry posits that antigens from pathogens such as viruses or bacteria may 
resemble myelin antigens closely enough that the immune system fails to differentiate 
between structurally similar self and non-self resulting in autoimmunity. It has been 
hypothesized that chronic inflammation may result in the activation of T cells of 
unrelated antigen specificities through a process called epitope spreading (McMahon et 
al., 2005).  
Rodent studies show that auto-reactive T cells activated in the periphery need to 
be re-stimulated upon arrival in the CNS. In vitro, microglia can be prompted to assume a 
dendritic cell (DC) phenotype through a multi-step activation process. Exposure to the 
hematopoietic growth factors such as granulocyte/monocyte colony-stimulating factor 
(GM-CSF) can prime microglia to enter a DC differentiation pathway (Aloisi et al., 2000; 




signal such as interferon gamma (IFN-γ) or LPS or exposure to activated T cells can push 
microglia into a fully competent antigen-presenting cell (APC) phenotype (Aloisi et al., 
2000; Ponomarev et al., 2007; Re et al., 2002; Shrikant and Benveniste, 1996).  
The state of microglial activation appears to dictate whether they can activate a T 
cell or induce anergy. Matyszak and colleagues report that microglia treated with GM-
CSF, IFN- γ or CD40 ligand (CD40L;     CD154) alone are not mature APCs. They also 
demonstrate that microglia only partially activated induce anergy in T cells whereas 
microglia in the presence of GM-CSF and a pro-inflammatory secondary signal promote 
T cell activation and proliferation (Matyszak et al., 1999).  
Given their competence in vitro as DCs microglia were initially thought to re-
stimulate encephalitogenic T cells during MS episodes. There is conflicting evidence 
whether this re-stimulation is accomplished by microglia or by infiltrating DCs from the 
periphery. Furthermore, the re-stimulation of T cells either by DCs and/or microglia is 
accompanied by the failure of the usual protective immunosuppressive mechanism(s) 
employed by the CNS. Studies indicate that at least some part of this failure may be a  





Astrocytes are the most abundant glial cell type in the CNS. Originating from the 
neuroectoderm during development, astrocytes are absolutely essential for maintaining 
the homeostatic conditions in the CNS (Dong and Benveniste, 2001; He and Sun, 2007; 
Malipiero et al., 1990). Immunohistochemically identified by the expression of glial 
fibrillary acidic protein (GFAP), astrocytes provide a stable environment for neurons by 
preventing fluctuations in local ion concentrations and pH (He and Sun, 2007). 
Moreover, they clear neuronal waste and prevent excitotoxicity by removing excessive 
neurotrasmitters such as glutamate from the synaptic cleft. Astrocytes also foster 
neuronal and oligodendrocyte survival by releasing BDNF, NGF and platelet-derived 
growth factor (PDGF) among others. In addition to these functions astrocytes maintain 
and regulate the blood brain barrier (BBB) (Aloisi et al., 1995; Becher et al., 2000b; 
Bechmann et al., 2007; Compston et al., 1997; He and Sun, 2007). 
Traditionally, the CNS has been viewed as an immune privileged site, partly as a 
consequence of its separation from the rest of the body by the BBB (Hickey, 2001; Suter 
et al., 2003). Though the BBB is highly permeable to water and lipid soluble molecules 
and possesses carrier mechanisms for essential nutrients, it generally inhibits the free 
passage of solutes from systemic circulation into the CNS (Hickey, 2001).  Also the CNS 
expresses very low levels of adhesion molecules necessary for the transit of immune cells 
into the CNS. Additionally, the CNS expresses copious amounts of TGF-β, a molecule 
that suppresses chemokine and adhesion molecule production as well as T cell 
proliferation (DeGroot et al., 1999; Li et al., 2006; Logan et al., 1992; Wesolowska et al., 




microenvironment of the CNS seems to be detrimental to the fate of the T cells that do 
enter the CNS. Numerous studies show that T cells at least in the healthy CNS are 
quickly eliminated through apoptosis. The proposed mechanisms include the withdrawal 
of T cell trophic factors such as IL-2 or IL-7, encounter with T regulatory cells, the 
activation of TNF receptor 1 and/or CD95-CD95L death-inducing pathways(Kwidzinski 
et al., 2005; Meinl et al., 1994).   
However, in the past few years the definition of CNS immune privilege has been 
refined. Evidence has steadily emerged demonstrating that during an immune response, 
activated T cells pass through the BBB and into the CNS irrespective of the involvement 
of CNS antigens in the initiation of the inflammation (Cayrol et al., 2008; Engelhardt, 
2006; Ifergan et al., 2008; Lees et al., 2006). Furthermore, contrary to prior opinion, CNS 
derived antigens have also been shown to drain to cervical lymph nodes where they may 
be endocytosed by DCs and presented to T cells in the periphery. Though the CNS has an 
elaborate mechanism that seems to discourage T cell activity, under certain conditions T 
cells can and do overcome this inhibitory effect. During infections or autoimmune 
MS/EAE, for example, T cells proliferate and accumulate in the CNS resulting in 
inflammation that is detrimental to the health of the organism (Becher et al., 1999; Cayrol 
et al., 2008; Dittel, 2008; Engelhardt, 2006; Kebir et al., 2007; Lees et al., 2006; 
McQuaid et al., 2009; Meinl et al., 1994).       
Until relatively recently, astrocytes were thought of only as “housekeeping” or 
“support cells,” and their immunological functions were somewhat overlooked. Though 
their capacity to activate T cells through antigen capture and presentation is controversial, 




chemokines. These include the cytokines IL-1, IL-6, IL-10, IFN-α, IFN-β, GM-CSF, 
TGF-β, TNF-α, PGE2 and the chemokines monocyte chemoattractant protein 1 (MCP-1, 
CCL2), IFN-γ inducible protein 10 (IP-10), CCL2, CCL3, CCL4, CCL5, CCL20, 
CXCL12 (Aloisi et al., 1995; Constantinescu et al., 1996; Dong and Benveniste, 2001; 
Farina et al., 2007; Frei et al., 1989; He and Sun, 2007; Malipiero et al., 1990; Mizuno et 
al., 1994b; Mizuno et al., 1994a; Ohno et al., 1990; Sawada et al., 1989; Sawada et al., 
1992).  These immunomodulatory proteins not only affect T cells that find their way into 
the CNS directly, but they can also affect T cells indirectly by influencing the maturation 
and or function of infiltrating peripheral DCs and of potential CNS DCs like microglia.  
There is some evidence that points to the modulatory affect of astrocytes on 
microglia and monocyte-derived cells. Astrocytes appear to down-regulate microglial 
expression of the IL-10 receptor (Ledeboer et al., 2002). Moreover, astrocyte-derived 
molecules down-regulate the production of IL-12 by microglia activated by IFN-γ/LPS 
(Aloisi et al., 1997). IL-12 suppression is mediated incompletely by soluble factors 
indicating that astrocytic cell membrane bound molecules may be important. Though the 
study did not identify the active molecules, IL-10 and PGE2 were found not to be 
responsible. Further evidence for the suppressive quality of astrocytes comes from a 
study conducted by Hailer and co-workers. Human peripheral blood-derived monocytes 
(PBMCs) activated with LPS in the presence of rat astrocytic supernatant expressed 
significantly lower levels of MHC Class II. Reduced PBMC MHC Class II expression 
could only be partially mimicked by the addition of exogenous IL-4, IL-10 or the 
receptor antagonist for IL-1 (Hailer et al., 1998). Furthermore, soluble astrocytic factors 




(HO-1) and inducible-nitric oxide synthase (iNOS) in a TGF-β mediated process (Min et 
al., 2010; Vincent et al., 1997). More importantly, microglia, in the presence of astrocytes 
or astrocytic-conditioned medium (ACM) were markedly less active/neurotoxic even 
when exposed to amyloid peptide (Aβ), a potent activator of microglia in vitro (von 
Bernhardi and Eugenin, 2004). Taken together these reports clearly demonstrate that 
astrocytes and microglia behave quite differently when they are together than when they 
are alone.  
2.3 Dendritic Cells 
Dendritic cells (DCs) are the primary antigen presenting cells (APCs) of the immune 
system, and play an important role in linking the innate (antigen-nonspecific) and the 
adaptive (antigen-specific) arms of the immune system (Banchereau et al., 2000; 
Banchereau et al., 2003; Banchereau and Steinman, 1998). As such, they are essential for 
the activation and maturation of naïve CD4
+
 T cells into fully functional T helper cells 
(Th cells). Additionally, DCs are also crucial for B-cell maturation, boosting antibody 
production, Ig class switching and cytotoxic T cell activities (Banchereau et al., 2000; 
Mellman and Steinman, 2001; Palucka and Banchereau, 1999a; Steinman et al., 1999; 
Thery and Amigorena, 2001). Furthermore, they play a critical role in preventing 
autoimmunity by tolerizing T cells to self antigens (Blanco et al., 2008; Coquerelle and 
Moser, 2008; Hawiger et al., 2001; Wallet et al., 2005). Newly-generated immature 
dendritic cells (iDCs) from the bone marrow migrate via the bloodstream and take up 
residence in peripheral tissues where they are poised to respond to any pathogenic 




In the periphery, the iDCs constantly sample their microenvironment through a 
variety of processes. These include macropinocytois, phagocytosis and endocytosis 
triggered by C-type lectin receptors, type I and II Fcγ receptors and various integrins that 
recognize apoptotic or necrotic cell death. “Self” antigens, arising as a consequence of 
apoptotic or necrotic cell death, and “non-self” antigens from invading pathogens are all 
efficiently captured and processed by iDCs (Basu et al., 2000; Manfredi et al., 2009; 
Maresz et al., 2007; Meloni et al., 2008; Sauter et al., 2000; Steinman et al., 2000). 
Though competent at capturing antigens, iDCs are poor activators of T cells since they 
either lack or express low levels of T cell stimulatory molecules such as major 
histocompatibility complex  I or II (MHCs), CD40, CD80 (B7.1) and CD86 (B7.2) 
(Dhodapkar et al., 2001; Hawiger et al., 2001; Jin et al., 2007; Jonuleit et al., 2001; 
Mahnke et al., 2002; Roncarolo et al., 2001; Steinman et al., 2003).  
The maturation of iDC from an antigen-capturing to an antigen-presenting 
phenotype capable of activating naïve T cells is a complex process. In order to finish 
maturation they must travel to the lymph nodes or the spleen and interact with T cells  
(Allavena et al., 1999; McColl, 2002). Changes in the expression of various chemokine 
receptors (CCRs) expressed by iDCs undergoing maturation facilitate their voyage to the 
secondary lymphoid organs. Chemokines such as macrophage inflammatory protein- 1α 
(MIP-1α/CCL3), MCP-1/CCL2) and the chemokine Regulated Upon Activation in 
Normal T cells, Expressed, Secreted (RANTES/CCL5) recruit CCR5- and CCR6-
expressing iDCs to the site of inflammation (Sallusto et al., 1998).  
As the iDCs mature, CCR7, the receptor for CCL19 and CCL21, is upregulated at 




2005). CCL19 is constitutively expressed by stromal cells and by mature DCs in the “T 
cell zone” of the secondary lymphoid organs. On the other hand, CCL21 is expressed 
mainly by cells of the lymphatic vessels. The restrictive expression of CCL19 and CCL21 
in the lymphoid organs coupled with the switch in the expression of CCRs in DCs 
undergoing maturation ensures that only iDCs that are sufficiently activated undergo 
migration (Sallusto et al., 1998). Once the iDCs reach the lymphoid organs, chemokines 
released by the maturing DCs attract naïve T cells. Naïve T cells expressing high 
quantities of CD40L complete the DC activation process by binding to CD40 on the 
maturing DCs (McColl, 2002; Sozzani et al., 1998). Besides T cells, mature DCs already 
present in the lymphoid organs can provide the final maturation signal to the maturing 
DCs by secreting cytokines such as TNFα and IFN-γ. Upon receiving maturation signals 
iDCs undergo significant phenotypical and morphological changes that culminate in the 
generation of fully mature APC. Changes in the expression of many cell surface receptors 
and various intracellular processes are observed during this time. Down-regulation of 
antigen uptake activities while up-regulating the T cell stimulatory molecules and 
cytokine secretion are some of the hallmarks of iDCs undergoing maturation. Compared 
to iDCs, mature DCs (mDCs) express high levels of MHC Class I and II, CD40, CD80, 
CD86 and various cytokines and chemokines (Lutz and Schuler, 2002; Turley et al., 
2000).  
iDCs are set upon the path to maturation when they encounter a “danger signal.” 
Various endogenous and exogenous cues can serve as the danger signal (Bianchi, 2007; 
Lotze et al., 2007a). Endogenous signals released by necrotic or damaged cells (but not 




heat shock proteins (HSP), nucleotides, or high mobility group 1 protein (HMGB1) can 
serve as activating signals. Human iDCs treated with HSP60, HSP70 or gp96 assume a 
mature dendritic cell phenotype (Bianchi, 2007; Flohe et al., 2003; Lotze et al., 2007a; 
Matzinger, 2002; Singh-Jasuja et al., 2000b; Singh-Jasuja et al., 2000a; Willart and 
Lambrecht, 2009). Likewise, HMGB1, a chromatin binding protein, passively released by 
necrotic cells can efficiently induce iDC maturation (Lotze et al., 2007b; Scaffidi et al., 
2002). Furthermore, iDCs can respond to pro-inflammatory cytokines including TNFα, 
IL-1α, and IL-4 that are produced during early stages of the immune reaction by innate 
immune system cells such as macrophages, neutrophils and eosinophils.  
   Exogenous signals in the form of PAMPs like LPS recognized by particular 
“pattern recognition receptors” (PRRs) such as those belonging to the Toll-like family of 
receptors (TLR) may also serve to induce iDC maturation (Akira et al., 2000; Bianchi, 
2007; Edwards et al., 2002; Kaisho and Akira, 2003; Kaisho and Akira, 2006; Medzhitov, 
2001; Miller et al., 2005; O'Neill, 2008). TLRs are the most widely studied PRRs in 
mammals. At least 10 different TLRs in humans and 13 in mice have been identified 
(Medzhitov and Janeway, Jr., 2000b). All TLRs share a common extracellular domain 
rich in leucine repeats and an intracellular Toll/interleukin-1 receptor (TIR) homology 
domain (O'Neill, 2008). The downstream signaling pathways for TLRs are activated by 
the binding of the appropriate ligand as illustrated in Table 2.2. 
Downstream TLR signaling can occur in one of two ways. All TLRs, with the 
exception of TLR 3, can activate either the MyD88 adapter dependent or independent 
pathway (Akira et al., 2000; Yamamoto et al., 2003). TLR 3 can only activate the 




ligation culminates with the activation of the transcription factors NF-kB, activating 
protein 1 (AP-1) and/or interferon regulatory factor 3 (IRF3). 
In the MyD88 dependent pathway, MyD88 is recruited to the intracellular TIR 
domain by the adapter protein TIR Activating Protein (TIRAP/MAL). MyD88 in turn 
recruits the IL-1 Receptor Associated Kinase (IRAK) family members IRAK-4 and 
IRAK-1 to further the signaling event. Phosphorylated IRAK-1 associates with the TNF 
Receptor Associated Factor-6 (TRAF-6) and activates it through phosphorylation. At this 
point the signal bifurcates with one arm leading to the activation of MAP kinases and 
AP-1 and the other arm leading to the activation of NF-κB by the ubiquitination and 
degradation of the NF-κB inhibitor, IκB. TLR activation of the MyD88 independent 
pathway requires the TIR domain-containing adapter inducing IFN-β (TRIF) protein. 
Intracellular TLR 3 activated by dsRNA can interact directly with TRIF. TRIF activation 
leads to the activation of the kinase IKK which phosphorylates the interferon regulatory 
factor-3 (IRF-3) and facilitates its nuclear translocation. The activation of the 
transcription factors NF-κB, AP-1 and IRF-3 can lead to the maturation and up-regulation 
of co-stimulatory molecules and secretion of chemokines and pro-inflammatory 












Table 2.2 TLRs and Their Ligands 
TLR Ligands 
TLR 1 Triacyl lipopeptides 
TLR 2 Peptidoglycan 
TLR 3 dsRNA 
TLR 4 LPS, taxol, HSP’s, 
envelop protein 
TLR 5 Flagellin 
TLR 6 Diacyl lipopeptides 
TLR 7 ssRNA 
TLR 8 ssRNA (only in 
humans) 
TLR 9 CpG DNA 
Source:  Takeda and Akira, 2007 
In the lymphoid organs, the captured and by-now-processed foreign antigen is 





 TCR respectively (Banchereau et al., 2000; Guermonprez et al., 2002; Mellman et 
al., 1998; Mellman and Steinman, 2001; Pierre et al., 1997; Wallet et al., 2005). This is 
one of the two signals required for T cell activation. The second signal is provided by co-
stimulatory molecules belonging to the B7 family (CD80, CD86) or CD40 (Avni and 
Rao, 2000; Brehin et al., 2008; Bretscher, 1999; Cardona et al., 2006; Chen et al., 2003; 
Green et al., 1995). These molecules engage their binding partners CD28/CTLA-4 and 








 T cells are critical mediators of the adaptive immune system. Activated T cells can 
recruit other members of the immune system such as B cells, basophils, and neutrophils 
by producing various cytokines and chemokines, to further bolster the immune response 
(Palucka and Banchereau, 1999b). Naïve CD4
+
 T cells responses can be polarized into at 
least four important categories: Th1, Th2, Th17 and Tregs . Of these, Th1 and Th17 are 
generally considered to be pro-inflammatory whereas, Th2 and Tregs are usually thought 
of as anti-inflammatory.    
The proper activation of naïve T cells requires two distinct signals. Evidence for 
the existence of a two-signal mechanism in T cell activation was first presented by 
Lafferty and Woolnough. In a report on the mechanism of allograft rejection, they 
proposed that proper T cell activation requires an “antigenic” as well as an “inductive 
stimulus.” They further claimed that neither stimulus by itself was sufficient to induce T 
cell activation (Lafferty and Woolnough, 1977). Further studies since then have proved 
this to be the case (Acuto et al., 2003; Tuosto and Acuto, 1998). Sufficiently mature DCs 
can supply T cells with the required signals, both in vivo and in vitro. In case of naïve 
CD4
+
 T cells, DCs present a captured and processed antigen peptide in the context of 
MHC II to the TCR to provide signal one. The TCR is a multi-subunit complex 
composed of variable α and β chains non-covalently linked to a non-variable CD3 unit 
(Dietrich et al., 1996). The variable αβ subunit of the TCR possesses the capacity to bind 
the multitude of antigens that may be encountered during the lifetime of an organism. 




cells in vitro may be activated by agonist CD3 antibodies without the help of  APCs or 
antigens (Hermans and Malissen, 1993; Wegener et al., 1992). Stimulation of the TCR 
leads to a complex chain of events that culminates in the activation of transcription 
factors including nuclear factor-κB (NF-κB) and nuclear factor of activated T cells 
(NFAT) (Masuda et al., 1998). The activation of NF-κB and NFAT results in the 
transcription of various genes necessary for the further maturation of T cells.  
In spite of all the changes in gene transcription and translation, signal one alone 
cannot elicit a proper response from T cells. Belying its name as mere “co-stimulation,” 
signal two is as important as the signal provided by the MHCII:antigen-peptide complex. 
Various B7 family members such as B7.1 (CD80), B7.2 (CD86), B7-H1/programmed 
death ligand-1 (PD-L1) and B7-H2 expressed by DCs can provide the secondary stimulus 
when they interact with their cognate receptors CD28, cytotoxic T-lymphocyte antigen-4 
(CTLA-4), inducible co-stimulator (ICOS) and programmed death (PD-1) expressed on T 
cells.  
T cells constitutively express CD28 (Gross et al., 1992). Stimulation of CD28 by 
either CD80 or CD86 can lead to the enhancement of IL-2 production which then acts in 
a paracrine/autocrine manner to promote T cell proliferation (Appleman et al., 2000; 
Lucas et al., 1995). Additionally, CD28 stimulation also increases the expression of the 
anti-apoptotic protein Bcl-xl in an IL-2 independent manner to further bolster the ability 
of T cells to resist apoptosis (Boise et al., 1995). Unlike CD28, CTLA-4, PD-L1 and 
ICOS are rapidly upregulated upon T cell activation (Latchman et al., 2004; Teft et al., 
2006). ICOS is a positive regulator of T cell function. ICOS stimulation after T cell 




cytokine secretion, especially for Th2 polarized cells (Watanabe et al., 2005). On the 
other hand, CTLA-4 and PD-L1 act negatively to limit the T cell response (Nishimura et 
al., 2001; Walunas et al., 1994). 
Co-stimulation can also be provided by stimulation of the T cell CD40L by 
CD40-expressing DCs (Fujii et al., 2004). CD40 is a member of the TNF super family of 
receptors and is expressed by a variety of cells such as DCs, monocytes, B and epithelial 
cells (van Kooten and Banchereau, 1997). Stimulation of CD40/CD40L pathway has 
been shown to improve the efficiency of DCs by upregulating their expression of 
CD80/CD86 while simultaneously providing T cells with a secondary stimulus (Quezada 
et al., 2004; van Kooten and Banchereau, 1997). 
Not only are DCs capable of activating T cells but they also have the capacity to 
modulate and fine-tune the T cell response. The strength and duration of DC signaling 
seems to play a role in determining the direction of the immune response, with evidence 
showing that a “strong” and prolonged signaling leads to type 1 inflammatory response 
(Th1), whereas a “weak” signal gives rise to anti-inflammatory Th2 responses (Bretscher, 
1999; Green et al., 1995; Guermonprez et al., 2002). Another important factor in 
determining T cell fate is the cytokine milieu present during their activation. To date, four 
main differentiation pathways have been identified for naïve CD4
+
 T helper cells. T cells 
can become T helper (Th) 1, -2, -17, or T regulatory cells (Tregs) (Murphy and Reiner, 
2002). Development of the appropriate subset of Th cells is of vital importance not only 
to fight off infections but also to prevent autoimmunity.  
DCs at different stages of maturation or belonging to different subsets can affect 




Depending on conditions, DCs can secrete many immunomodulatory chemokines and 
cytokines that can affect the quality of the immune response. For instance, DCs 
stimulated by LPS primarily secrete IL-12 and stimulate a pro-inflammatory Th1 
response (Hsieh et al., 1993; Murphy et al., 1997).  
2.4.2 Th1 Cells 
First described more than two decades ago by Mosmann and Coffman, Th1 and Th2 cells 
are probably the most widely studied subsets of T helper cells (Mosmann et al., 2005). In 
that seminal study, two distinct clones of T cells were identified, based mainly on the 
production of certain “signature” cytokines. Since then, knowledge of these two closely 
related Th cells has expanded considerably. 
Th1 is a pro-inflammatory phenotype of T cell characterized by high production 
of IFN-γ, lymphotoxin-α (LT-α/TNF-β), and IL-2. Naïve CD4
+
 cells can be polarized 
into attaining a Th1 phenotype on TCR stimulation in the presence of IL-12 (Manetti et 
al., 1993). DCs activated by TLR ligation or pro-inflammatory cytokines acquire the 
ability to produce copious amounts of IL-12. IL-12 is a heterodimeric pro-inflammatory 
cytokine and the founding member of the IL-12 family of cytokines which also includes 
IL-23, IL-27 and IL-35. An IL-12-specific p35 subunit combines with a common p40 
subunit to form bioactive IL-12p70 (Trinchieri et al., 2003). DCs and other innate 
immune cells such as monocytes, neutrophils and natural killer (NK) cells are able to 
produce IL-12. Naïve T cells constitutively express the receptors for IFN-γ and IL-
12Rβ1, which act together with the inducible β2 subunit to confer IL-12 sensitivity (Chua 
et al., 1995; Presky et al., 1996; Wu et al., 1996). IL-12β2 subunit expression is rapidly 




dependent manner (Kano et al., 2008). The activation of IRF-1 is a critical step in making 
T cells responsive to the effects of IL-12. Abrogation of IRF-1 signaling in vivo or in 
vitro results in a significant skewing of the Th response in favor of Th2 cells while 
simultaneously reducing the number of Th1 cells significantly (Taki et al., 1997).  
IL-12 acts in an autocrine manner to maintain its own expression through the activation 
of signal transducer and activator of transcription-4 (STAT-4) (Nishikomori et al., 2002). 
The activation of STAT-4 also leads to the production of IFN-γ, that acts in a 
paracrine/autocrine manner to activate STAT-1 and the Th1-specific transcription factor 
“t-bet” (Lighvani et al., 2001; Szabo et al., 2000). Moreover, IFN-γ can initiate the Th1 
developmental pathway by itself in the absence of IL-12 though not as efficiently as IL-
12 (Lugo-Villarino et al., 2003). The activation of STAT-1 stabilizes the expression of 
the IL-12R complex thereby maintaining Th1 IL-12 responsiveness over their lifetime. 
Interestingly, the expression of STAT-1 appears to be absolutely required to promote Th1 
development only in the presence of both Th1 and Th2 polarizing cytokines. The deletion 
of STAT-1 in the absence of Th2 cytokines and in the presence of IL-12 does not affect 
the ability of CD4
+
 T cells to become Th1 cells (Afkarian et al., 2002). However, the 
expression of t-bet is required in all instances and naïve T cells lacking t-bet cannot 
efficiently differentiate into Th1 cells (Szabo et al., 2000). 
Proper Th1 responses are critical for the clearance of certain intracellular 
pathogens such as protozoa, bacteria and fungi. IFN-γ, the main effector cytokine 
produced by Th1 cells, is indispensable for their action.  For instance, infections by the 
bacterium Listeria monocytogenes require a robust Th1 response to be cleared (Scott et 




the etiology of many autoimmune disorders, the role of Th1 cells has been significantly 
downgraded upon the recent discovery of Th17 cells and findings about their role in 
autoimmune pathology (See below). 
2.4.3 Th2 Cells 
Along with Th1 cells, Th2 cells were one of the two subsets of Th cells originally 
described by Mosmann et al. in 1986. Th2 cells are considered primarily to be anti-
inflammatory in nature and are defined by their production of the cytokines IL-4, IL-5, 
IL-9, IL-10, IL-13 and IL-25 (Mosmann et al., 1986; Swain et al., 1988; Zhu and Paul, 
2008).  While mostly anti-inflammatory in nature, Th2 cells are responsible for airway 
allergy inflammation and are required for efficient action against certain extracellular 
pathogens such as helminthes and nematodes (Zhu and Paul, 2008). Furthermore, the 
cytokines produced by Th2 cells can promote antibody class switching by B cells (Sher et 
al., 1990).  
Not unlike Th1 cells, the polarization of Th2 cells also depends on TCR signaling 
and the presence of the requisite cytokines in the immediate microenviroment. IL-4, the 
signature cytokine produced by Th2 cells, is also required to initiate their development 
from CD4
+
 naïve T cells (Swain et al., 1990). In vitro, T cells can be polarized into Th2 
cells by TCR stimulation in the presence of exogenous IL-4. Moreover, Th2 cells can 
also be generated in the absence of exogenously added IL-4 through TCR stimulation and 
the simultaneous blockade of Th1 polarizing signals. Upon TCR stimulation CD4
+
 T 
cells produce low amounts of IL-4 which appear to be sufficient to elicit a positive 
feedback loop resulting in Th2 differentiation when antagonizing stimuli are neutralized 




plays an important role in Th1 or Th2 polarization. Naïve T cells weakly stimulated by 
DCs tend to produce low quantities of IL-4 and IL-2 which act in a paracrine manner to 
drive Th2 polarization whereas a strong TCR stimulation leads to a Th1 phenotype.  
The presence of exogenous or endogenous IL-4 when the TCR is activated leads 
to the induction of the Th2-specific transcription factor GATA binding protein-3 (GATA-
3) in a STAT-6 dependent manner (Ho et al., 2009; Pai et al., 2004). STAT-6 is both 
necessary and sufficient for IL-4 signal transduction and Th2 induction (Zhu et al., 2001). 
Conditional knockout studies of GATA-3 provide ample evidence of the role GATA-3 
plays in directing Th2 cell function Studies using STAT-6 negative mice prove that 
activation of GATA-3, independent of IL-4/STAT-6, pathway is sufficient for Th2 
differentiation and function (Zheng and Flavell, 1997). Although IL-4 is required for Th2 
differentiation, recent evidence reveals that IL-2 induced STAT-5 may be just as 
important as IL-4 induced GATA-3 signaling. Neutralizing IL-2 signaling in vitro in the 
presence of the requisite Th2-polarizing conditions results in a near elimination of Th2 
cells (Cote-Sierra et al., 2004). Furthermore, the effect of IL-2 was a result of impaired 
Th2 differentiation and was independent of cell survival or proliferation. The same study 
also reveals that IL-2 signaling is not required for the induction of Th2 differentiation;     
rather it is required for the continued expression of the Th2 phenotype, and it does so by 
maintaining the accessibility of the IL-4 gene to transcription factors. These findings 
have been recapitulated in vivo.   
A dichotomy of sorts exists between Th1 and Th2 phenotypes. Under 
unambiguous polarizing conditions, induction of t-bet actively antagonizes GATA-3 and 




of the phenotype associated with that particular factor both in vivo and in vitro, even in 
the most favorable of polarizing stimuli. Unlike t-bet, GATA-3 is expressed at a very low 
level under basal conditions and seems to negatively affect t-bet transcription. The 
deletion of basal GATA-3 signaling promotes Th1 induction even under strong Th2-
promoting and Th1-impeding stimuli (Pai et al., 2004). It appears that the basal levels of 
GATA-3 are required for the maintenance of an immature phenotype in naïve CD4
+
 T 
cells and to prevent “spontaneous” Th1 polarization. 
2.4.4 Th17 Cells 
Th17 cells are a relatively newly-identified subset of T cells and are so named due to 
their ability to efficiently produce the pro-inflammatory cytokine IL-17 (Harrington et al., 
2005). IL-17 is an inflammatory cytokine with roles in inflammation and autoimmune 
disorders. In addition to their main effector cytokine, Th17 cells can also produce IL-17F, 
IL-6, TNF, IL-21 and IL-22. The development and regulation of these cells has remained 
obscure until the past few years. Various studies have shown that efficient Th17 
polarization from naïve CD4
+
 T cells can be achieved through the combined action of 
TGF-β and IL-6/IL-21 and IL-23 at distinct points during the differentiation process or 
IL-1β, IL-6 and IL-23 simultaneously.   
 Naïve CD4
+
 T cells can be induced to differentiate into Th17 cells by TGF-β and 
IL-6 or IL-21 (Korn et al., 2007; Veldhoen et al., 2006). Because TGF-β is primarily anti-
inflammatory in nature whereas IL-6 and IL-21 are pro-inflammatory, it is surprising that 
cytokines with apparently contradictory characteristics can work together to induce Th17 
polarization. TGF-β by itself can generate T regulatory cells (Tregs, see below), but the 




There is conflicting information about the requirement of TGF-β in Th17 polarization 
with the majority of reports claiming that TGF-β is absolutely required for Th17 
differentiation. Mice with TGF-β-unresponsive CD4
+
 T cells appear to be unable to 
produce Th17 cells whereas mice with CD4
+
 T cells that overexpress TGF-β have 
significantly more Th17 cells (Qin et al., 2009). However, a very recent study by 
Ghoreschi et al. reports that IL-1β with IL-6 and IL-23 can also induce Th17 cells from 
naïve T cells in the absence of TGF-β (Ghoreschi et al., 2010). 
IL-6 was originally thought to be as indispensable as TGF-β for Th17 induction. 
However, in vitro, Th17 cells can also be generated from naοve CD4
+
 T cells by TGF-β 
and IL-21. Although IL-21 can efficiently replace IL-6 in vitro, the scenario in vivo is 
peculiar. IL-6 knockout mice can produce Th17 cells only upon the depletion of naturally 
occurring Tregs (Korn et al., 2007). During pathological conditions a variety of cells 
including Th1, Th2, NK cells, and T follicular cells can produce IL-21 (Suto et al., 2008). 
It would appear that TGF-β and IL-21 produced by other immune cells coupled with the 
abrogation of normal anti-inflammatory controls can produce Th17 cells even in the 
absence of IL-6.  
TGF-β and IL-6/IL-21 acting through the SMAD and STAT-3 pathways 
respectively lead to the induction of the Th17-specific transcription factor RAR-related 
orphan receptor gamma (RORγt) (Ivanov et al., 2006). Activation of SMAD or STAT-3 
alone is not sufficient to induce fully functional RORγt. STAT-3 deficient mice cannot 
induce RORγt and are, therefore, incapable of generating Th17 cells (Wei et al., 2007). 
Interestingly, a study by Zhou and colleagues suggests that TGF-β alone may be enough 




post-translational mechanism and IL-6 or IL-21 through STAT-3 somehow relieve 
RORγt suppression (Xiao et al., 2008; Zhou et al., 2007). Additionally, STAT-3 leads to 
the upregulation of IL-21 production by Th17 cells undergoing polarization. IL-21 acts in 
a self-amplifying loop to increase Th17 cell numbers by promoting their survival and by 
actively inhibiting the differentiation of Th1 cells leading to skewing of the Th cell 
repertoire towards the Th17 phenotype (Wei et al., 2007). And as noted above, under 
certain situations in vivo, IL-21 produced by innate immune cells may substitute for IL-6.  
In addition to TGF-β, IL-6 and IL-21, IL-23 stimulation of T cells undergoing 
Th17 differentiation is required to stabilize their phenotype and complete the maturation 
process (Langrish et al., 2005). IL-23 is a heterodimeric cytokine belonging to the IL-12 
family of cytokines. It is composed of the novel IL-23p19 and the IL-12 shared IL-12p40 
subunits (Oppmann et al., 2000). It is important to note that IL-23 is not a Th17 
differentiation factor and naïve CD4
+
 T cells do not express the IL-23 receptor 
(McGeachy et al., 2009). Nonetheless, the activation of RORγt and STAT-3 leads to the 
expression of IL-23R on T cells stimulated with TGF-β and IL-6/IL-21 thus rendering 
them responsive to IL-23 (Xiao et al., 2008). IL-23 derived from innate immune cells 
such as DCs and macrophages acts on Th17 cells to not only maintain their phenotype 
but also to promote their survival. In fact, mice lacking IL-23p19 or IL-23R cannot 
generate Th17 cells in substantial numbers (Cua et al., 2003; Langrish et al., 2005; 
McGeachy et al., 2009). Furthermore, since uncontrolled inflammation is detrimental to 
the health of the organism, Th17 sensitivity to IL-23 may also serve to limit the duration 
and potency of Th17 mediated inflammation. However, Ghoreschi at al. report the 




but also differs in significant ways. In their hands IL-1β in conjunction with IL-6 and IL-
23 was also able to induce Th17 differentiation independent of TGF-β. The upregulation 
of IL-23R through IL-6-dependent activation of STAT-3 renders differentiating T cells 
responsive to IL-23, which then acts in a positive feedback manner to further upregulate 
IL-23R and Th17 polarization (Ghoreschi et al., 2010). Although contrary to prior 
opinion suggesting that TGF-β and IL-6 have both been shown to be dispensable, IL-23 
still appears to be required for Th17 polarization. 
Th17 cells are an essential part of the adaptive immune system and their proper 
function is obligatory for the health of an individual. A well-regulated Th17-derived 
cytokine response is absolutely critical for the proper clearance of certain bacterial and 
fungal infections (Khader et al., 2007; Rudner et al., 2007; Ye et al., 2001). The exposure 
of naïve Th cells to cell components of particular pathogens seems to polarize them 
towards a Th17-inducing phenotype characterized by high expression of IL-23 and IL-6 
among other cytokines (Infante-Duarte et al., 2000). In addition to contributing to host 
defense, Th17 cells have also been identified to play a critical role in the etiology of 
many autoimmune diseases. These include psoriasis, rheumatoid arthritis (RA), MS, 
inflammatory bowel disease (IBD) and asthma (Komiyama et al., 2006; Murphy et al., 
2003; Zheng et al., 2007).  
The discovery of Th17 cells has fundamentally changed the understanding of  
autoimmune disorders. Studies utilizing rodent models or MS and RA have provided 
many insights into the mechanism of Th17-mediated autoimmunity. These disorders were 
originally thought to be the result of unchecked Th1 related activities. However, support 




Studies using mice deficient in the molecules required for Th1 differentiation 
conclusively show that EAE and collagen-induced arthritis (CIA) are Th17-dependent 
conditions. IL-12 receptor KO mice which are unable to induce Th1 polarization, as well 
as mice with IFN-γ-unresponsive T cells remain highly susceptible to EAE (Krakowski 
and Owens, 1996) suggesting an alternative T cell requirement. Furthermore, Gran et al. 
show that targeted deletion of the IL-12p40 (a subunit shared with IL-23) but not of IL-
12p35 confers immunity against EAE induction in mice (Gran et al., 2002). Taken 
together, these revelations provide an explanation for the discrepancies regarding Th1 
cells being the cause of certain autoimmune disorders. Inadvertent interference with 
molecules required for Th17 polarization while examining the roles of IL-12 and Th1 
cells may have led to the mistaken conclusion that Th1 cells were the culprits in 
autoimmunity. Further evidence against Th1 cells and in favor of Th17 cells comes in the 
form of adoptive transfer studies. When transferred into naïve mice, myelin basic protein 
(MBP) specific Th17 cells induce potent EAE whereas transfer of Th1 or Th2 cells does 
not (Stockinger et al., 2007).  
Intriguingly, the two Th17 polarization pathways described above appear to give 
rise to subsets of Th17 cells with very distinct phenotypes. T cells polarized in the 
presence of TGF-β and IL-6 seem to be non-pathogenic in relation to autoimmune 
diseases and have the capacity to produce anti-inflammatory IL-10 and IL-9 while 
suppressing pro-inflammatory IL-22 secretion (McGeachy et al., 2007). On the other 
hand, T cells polarized in the absence of TGF-β and in the presence of IL-1β and IL-23 
have a greater potential to cause autoimmune harm. The pathogenic subset of Th17 




their capacity to produce IFN-γ. Additionally, they also express markers such as IL-18R1 
and CXCR3 that have been shown to be prevalent during episodes of autoimmunity 
(Ghoreschi et al., 2010). 
2.4.5 T–Regulatory Cells 
In a healthy individual, pro- and anti-inflammatory events are kept on a tight leash. This 
tight control helps the immune system to respond appropriately to various pathogens and 
prevents autoimmunity. The job of preventing autoimmunity falls to a subset of Th cells 
called T regulatory cells (Tregs). The hypothesis that there exists an innate regulatory 
mechanism to keep the immune system in check and autoimmunity at bay has been 
around for decades. Initial evidence for this hypothesis came from studies examining the 
role of the thymus in the immune system. It was observed that neonatally thymectomized 
rodents developed a “wasting disease” similar to “host vs. graft” syndrome as a result of 
severe autoimmunity (Yunis et al., 1967). This broad hypothesis has been refined over 
the past few years and accumulating evidence has identified Tregs as playing the crucial 
role of preventing autoimmunity.  
Sakaguchi et al. identified a subset of CD4
+
 T cells expressing the IL-2 receptor 
α-chain, as a key mediator of autoimmunity (Sakaguchi et al., 1995). Adoptive transfer of 
CD4
+
 T cells depleted of CD25
+
 cells into nude mice was able to spontaneously produce 
severe autoimmunity in the host whereas transfer of CD4
+
 cells containing CD25
+
 T cells 





 cells and therefore develop autoimmunity as a result of self-
reactive T cells (Sakaguchi et al., 1996). The discovery of a new Treg-specific 




study of these cells and has led to important findings about the mechanism behind their 
differentiation and mode action. Brunknow et al. identified Foxp3 deficiency as the cause 
of autoimmunity in “scurfy” mice (Brunkow et al., 2001). Mice affected with scurfy are 
remarkably similar to neonatally thymectomized mice in that both conditions are 
characterized by excessive proliferation of CD4
+
 T cells resulting in death within weeks 
of birth. Significantly, a scurfy-like human disease called immune dysregulation 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) has been shown to be a 
consequence of mutant Foxp3 (Bennett et al., 2001). Moreover, utilizing Foxp3 KO mice, 




 regulatory T 
cells originally identified by Sakaguchi et al. is contingent upon the expression and 
proper function of Foxp3 (Fontenot et al., 2003; Fontenot et al., 2005). Furthermore, they 




 cells could be endowed with suppressive functions simply 







 T cells have been classified into innately occurring natural 
Tregs (nTregs), produced in a fully mature state by the thymus or inducible Tregs (iTregs) that 
are generated locally in the periphery as required in response to various self and non-self 
antigens (Bensinger et al., 2001). Though nTregs and iTregs essentially perform the same 
function in the host and share certain traits, there are important differences between them. 
nTregs acquire a suppressive phenotype as a consequence of strong TCR stimulation by 
DCs presenting self-antigen and co-stimulatory interactions between CD28 and 
CD80/CD86 in a thymic microenvironment (Guo et al., 2008; Jordan et al., 2001; 
Salomon et al., 2000). Conditional deletion of the co-stimulatory molecules significantly 




implicated in nTreg development, though their involvement is controversial (Curotto de 
Lafaille et al., 2004; D'Cruz and Klein, 2005). Unlike nTregs, TGF-β and IL-2 seem to be 
indispensable for the development of iTregs, both in vitro and in vivo (Guo et al., 2008). 
Furthermore, it is also clear that maintenance of the suppressive phenotype by nTregs and 
iTregs is contingent upon the availability of TGF-β and IL-2 in the immediate cytokine 
milieu.  
   Naïve CD4
+
 T cells are set on the path towards acquiring an iTreg phenotype 
through the combined efforts of TGF-β-activated transcription factor SMAD-3 and TCR 
activated transcription factor NFAT. SMAD-3 and NFAT bind a Foxp3 enhancer region 
and drive its transcription. NFAT, in addition to binding to the Foxp3 enhancer region, 
also upregulates the expression of IL-2 and its receptor CD25 on T cells destined to 
become iTregs (Wu et al., 2006). Unlike conventionally activated T cells which upregulate 
CD25 only transiently, iTregs (and nTregs) maintain their expression of CD25 throughout 
their life as a Treg. This is an important distinction since induction and maintenance of 
Foxp3 requires IL-2-induced STAT-5 signaling (Wu et al., 2006). Mice deficient in IL-2 







 number of cells both in the periphery and in the 
thymus resulting in severe autoimmune disorders (Burchill et al., 2007). However, this 
defect can be rescued through the constitutive ectopic expression of STAT-5 (Antov et 
al., 2003). Moreover the study by Burchill et al. also shows that STAT-5 drives Treg 
development by binding the promoter region of the Foxp3 gene thus regulating its 
transcription (Yu et al., 2009). Interestingly, the effects of IL-2 but not those of the IL-











 Tregs whereas double IL-2 and IL-15 KO mice mimic 
the phenotype seen in IL-2Rβ KO mice (Burchill et al., 2007). Also, it appears that Tregs 
can be generated and maintained even under suboptimal IL-2/IL-15 signaling. Using a 
transgenic mouse model that expresses a mutant form of IL-2Rβ that can activate STAT-
5 weakly and only transiently, Yu et al. demonstrate that Tregs remain prevalent and 
functional (Yu et al., 2009). 
Tregs can exert their influence on the immune system in many ways. They can 
secrete large amounts of immunosuppressive cytokines such as TGF-β, IL-10 and IL-35 
(Collison et al., 2009; Taylor et al., 2006). TGF-β and IL-10 are well known suppressors 
of the immune system both in vitro and in vivo. IL-35 is a newly-identified member of 
the IL-12 family of cytokines.  Like the rest of its family members, IL-35 is a 
heterodimer consisting of the IL-12p35 subunit and a novel Epstein barr virus-induced-3 
(EBI-3) subunit (Niedbala et al., 2007). Unlike IL-12 and IL-23, IL-35 possesses anti-
inflammatory properties and has been implicated as a potential Treg-mediated supressive 
mechanism (Collison et al., 2007). In vitro, stimulation of Tregs with IL-35 under co-
stimulatory conditions promotes their proliferation (Castellani et al., 2010). Furthermore, 
the presence of IL-35 in the cytokine milieu suppressed the differentiation of Th1 and 
Th17 cells. In addition, exogenous administration of IL-35 reduced the severity of CIA in 
vivo (Niedbala et al., 2007).    
Tregs have also been reported to mediate immune suppression through contact-
mediated inhibition of DC maturation and/or function. In vitro, co-culture of mature DCs 




CD86 expressed by the DCs (Cederbom et al., 2000). This was later found to be mediated 
by CTLA-4, which is expressed constitutively by Tregs (Takahashi et al., 2000). Treg-
bound CTLA-4 stimulation of mature or maturing DCs turns them into poor stimulators 
of T cell activation. Furthermore, CTLA-4 stimulation also plays a critical role in 
controlling inflammation in a mouse model of inflammatory bowel disease (Read et al., 
2000). By producing the enzyme indoleamine 2,3-dioxygenase (IDO), CTLA-4-
stimulated DCs can induce apoptosis in activated T cells by depriving them of tryptophan 
(Fallarino et al., 2006). IDO is the enzyme responsible for tryptophan catabolism and thus 
reduces the amount of tryptophan available to T cells in the immediate microenvironment 
resulting in the apoptosis of nearby activated Th cells (Lee et al., 2002a).   
In addition to this, two unconventional yet equally effective mechanisms of Treg-
mediated control of inflammation have been proposed: Granzyme B-mediated cytolysis 
of effector T cells and Treg-induced cytokine deprivation resulting in effector T cell 
apoptosis. Tregs obtained from granzyme-B deficient mice show a reduced capacity to 
suppress T effectors as a result of being incapable of inducing granzyme B-mediated 
cytolysis in the target T effector cells (Gondek et al., 2005). Building on this study, Cao 
et al. demonstrated in vivo, that Tregs induced by a tumor microenvironment (in a yet 
unknown mechanism) were incapable of suppressing the host immune response against 
the tumor cells if the Tregs were granzyme B- and perforin-deficient (Cao et al., 2007).   
Death of effector T cells through cytokine deprivation is yet another suppressive 
mechanism available for Tregs. A study by Pandiyan and colleagues suggests that Tregs 
might literally “consume” more than their share of various cytokines thus depriving other 




2007). Also, this mechanism seems to be functional only when the Tregs are in close 
proximity to the Th cells since separation of the two subsets with a Transwell  apparatus 
abrogates Treg suppression.  
The dichotomous relationship between Th1 and Th2 cells seems to be 
recapitulated with Th17 and Tregs (Bettelli et al., 2006). Furthermore, a functionally 
antagonistic relationship also exists between the two. The decision of a naïve T cell to 
embark on either a Treg or a Th17 polarization pathway appears to be the result of the sum 
of all the favorable stimuli weighed against all the opposing stimuli. In the presence of 
appropriate stimuli, Foxp3 and RORγt both have the capacity not only to antagonize each 
other’s induction but also have the capability to reprogram an already differentiated T 
cell (Zhou et al., 2008). As previously stated, TGF-β in combination with IL-6 or IL-21 
can drive Th17 polarization and both nTregs and iTregs produce TGF- β. Evidence 
demonstrates that IL-6 stimulation can not only inhibit the suppressive functions of a 
nTreg but it can also reprogram the nTreg into a Th17 cell capable of IL-17 production 
(Zheng et al., 2008). iTregs do not seem to be affected in the same manner; moreover, they 
retain their suppressive capacity in the presence of IL-6, at least in vitro. 
2.5 Maintenance of Tolerance and Prevention of Autoimmunity 
Tolerance against self-antigens is a vital component of the healthy immune system. 
Several mechanisms seem to work in conjunction with each other to tolerize the immune 
system against self antigens and prevent autoimmunity. These mechanisms can be 
roughly classified into central and peripheral tolerance. 
In the so-called “central” or “thymic” tolerance, developing T cells that react 




Tregs (Hollander and Peterson, 2009; Jordan et al., 2001). In this first line of defense 
against autoimmunity, developing T cell progenitors interact with cortical thymic 
epithelial cells (CTEC) in the cortex of the thymus in a process that can, in the absence of 
further stimulus, result in apoptosis of the progenitor cell. T cell progenitors are 
prevented from undergoing apoptosis when they encounter and respond appropriately to 
co-stimulation and an MHC/self-antigen complex on DCs in the medulla of the thymus 
(Murphy et al., 1990; Punt et al., 1994). Only those that react with a moderate affinity to 
the stimulation are allowed to persist while those that react too strongly or not at all are 
“deleted” (Starr et al., 2003). However, the efficacy of this mechanism is limited by 
several factors. For instance, not all self antigens may find their way to the thymus. As a 
consequence, some T cells invariably escape the editing mechanism in the thymus. In 
addition to negatively selecting for T cells that react too strongly, the thymus also 
produces a phenotype of suppressive T cells called natural Tregs (nTregs) (Pacholczyk et 
al., 2002). These nTregs then migrate to the periphery where they exert their function. 
Curiously enough, the same mechanism that deletes self-reactive T cells also gives rise to 
nTregs (See below).  
According to some studies, up to 25%-40% of developing T cells may escape 
negative selection and enter the periphery. Unchecked, these T cells have the potential to 
cause harm through autoimmune disorders. The job of suppressing the activity of these 
potentially harmful falls to nTregs or peripherally generated Tregs called inducible Tregs 
(iTregs). DCs play a vital role in maintaining tolerance by generating iTregs to suppress 
autoreactive T cells in the periphery (Banchereau et al., 2003; Coquerelle and Moser, 




2005). Moreover, DCs also terminate the T cell response at its conclusion. The activation 
of “co-inhibitory” CTLA-4 or PD-1 by DCs at the appropriate time can prevent wayward 
T cell responses and potential autoimmunity. CTLA-4 can be activated by either CD80 or 
CD86 whereas, PD-1 can be stimulated by PD-L1. During the course of a normal T cell 
response CTLA-4 and PD-1 help to inhibit T cells in part by downregulating the 
production of IL-2 and induction of cell cycle arrest that eventually leads to apoptosis 
(Fife and Bluestone, 2008; Guleria et al., 2007). However, in the absence of either 
CTLA-4 or PD-1, mice develop severe autoimmune/ lymphoproliferative disorders 
resulting in their death within a few weeks (Latchman et al., 2004; Nishimura et al., 
2001; Vijayakrishnan et al., 2004).      
It is hypothesized that in the “steady state” characterized by the absence of 
inflammation, iDCs with their high phagocytic rate and low expression of stimulatory 
molecules, tolerize T cells to self antigens whereas iDCs matured in response to non-self 
antigens and accompanying danger signals evoke an immune response (Lutz and Schuler, 
2002; Steinman and Nussenzweig, 2002; Tan and O'Neill, 2005; Wallet et al., 2005).  
Evidence for the role of APCs and particularly DCs in producing tolerance in the 
periphery was been obtained relatively recently. Finkelman et al. demonstrated that APCs 
in addition to being immunogenic can also be tolerogenic (Finkelman et al., 1996). Mice 
injected with a rat monoclonal antibody (mAb) alone in the absence of other stimulatory 
signals induced antigen-specific T cell and B cell tolerance. This study, however, did not 
address the mechanism of tolerance induction or the specific type of APC responsible for 
it. Adler and colleagues reported that tolerizing of T cells through anergy to specific 




antigen-specific T cells (Adler et al., 1998). By selectively targeting the antigen hen egg 
lysozyme (HEL) to a sub-population of APCs expressing the endocytic receptor DEC-
205 Hawiger et al. were able to show that during steady state, DEC-205-expressing DCs 
captured the antigen and presented it to adoptively transferred HEL-specific T cells 
inducing tolerance by anergy and deletion. By contrast, the same antigen in the presence 
of co-stimulatory CD40L elicited a profound pro-inflammatory immune response in vivo 
(Hawiger et al., 2001).  
iDCs along with other phagocytic cells play an essential role in clearing the body 
of apoptotic cells (a prime source of self antigens). Numerous studies show that DCs 
presenting antigens derived from apoptotic cells will induce T cell tolerization in the 
periphery (Basu et al., 2000; Chen et al., 2001a; Sauter et al., 2000; Steinman et al., 
2000). By loading ovalbumin (OVA) into apoptotic cells and transferring them to 
syngeneic hosts, Liu et al. were able to induce experimental peripheral tolerance in mice. 
Mice thus tolerized were resistant to further immune stimulation by OVA even in 
complete Freund’s adjuvant. The same transfer of apoptotic cells in the presence of 
CD40L, however, did not induce tolerance (Liu et al., 2002).  
In addition to inducing tolerance directly by anergizing and deleting self 
responsive T cells, DCs can induce tolerance indirectly by inducing the differentiation of 
Tregs (Coquerelle and Moser, 2008; Steinman et al., 2003; Workman et al., 2009). Certain 
subsets of DCs present in antigen-rich environments such as the intestines, lungs and skin 
are especially proficient in generating iTregs. For instance, DCs associated with the lamina 
propria of the small intestine turn naïve CD4
+
 T cells into iTregs through a retinoic acid-




microenvironment present while DCs are undergoing maturation also seems to play a role 
in their promotion of tolerogenic T cell responses. A well defined example of this is DCs 
matured in the presence of anti-inflammatory IL-10 (DC-10).  DC-10s can induce oral 





POTENTIAL SOLUBLE CANDIDATES 
3.1 PGE2 
In the studies here, astrocytes prevent the microglial assumption of a mature DC 
phenotype. Possible astrocyte-derived soluble molecules are proposed as possible 
mediators of this response. Among these are prostaglandins, IL-10 and TGF- . 
Prostaglandins are a class of small lipid molecules derived from arachidonic acid 
(AA) (Needleman et al., 1986). Prostaglandins have the capacity to modulate a wide 
variety of bodily functions including the immune system (Gualde and Harizi, 2004; 
Harizi and Gualde, 2002). The conversion of AA into prostaglandins begins at the 
cytosolic face of the cell membrane. AA cleaved by phospholipase A2 from membrane 
phospholipids is acted upon by prostaglandin H synthase (also called cyclooxygenase 
[COX]) to form the intermediate common precursor PGH2. PGH2 is in turn converted 
into the different prostanoids by the action of cell-specific synthases. COX is the rate-
limiting enzyme in the synthesis of prostanoids (Needleman et al., 1986). There are two 
forms of COX. COX-1 is constitutively expressed and is responsible for basal synthesis 
of prostanoids within the body whereas the expression of COX-2 can be altered by a host 
of modulators. The expression of COX-2 and its metabolites have been demonstrated to 
play important roles during the course of inflammation (Boniface et al., 2009; Cheon et 
al., 2006; Lee et al., 2002b).  
There are five different prostaglandins: PGE2, PGI2, PGD2, PGE2α, and 
thromboxane (TXA2) (Needleman et al., 1986). Among these PGE2 is the most widely 







characterized (Johann et al., 2008).  
The expression of PGE2 is tightly regulated by COX2. LPS, IL-1, and TNF-α can 
induce COX2 whereas anti-inflammatory IL-10 and IL-4 can downregulate the enzyme’s 
expression. PGE2 has been reported to have a dual role in the immune system. Possessing 
both pro- and anti-inflammatory properties, PGE2 is capable of regulating DC activation, 
antigen presentation, migration and survival (Boniface et al., 2009; Kabashima et al., 
2003; Slepko et al., 1997; Vassiliou et al., 2003). By downregulating DC-
attracting/activating chemokines and cytokines and up-regulating anti-inflammatory 
agents, PGE2 can prevent DCs not only from migrating into an inflamed region but can 
also prevent and or quell the activation of DCs already in the vicinity. Conversely, by 
enhancing the maturation, survival and migration of certain sub-types of DCs like 
Langerhans cells, PGE2 can operate as a pro-inflammatory agent (Kabashima et al., 
2003). For example, PGE2 can synergize with TNF-α or IL-1β to efficiently promote the 
maturation of DCs. However, it can also inhibit the production of the chemokines CCL-
3/4 and inflammatory cytokines such as TNF-α and IL-12 while up-regulating the 
expression of IL-10, an anti-inflammatory cytokine (Aloisi et al., 1999; Minghetti et al., 
1998; Vassiliou et al., 2003). Moreover, PGE2 can also suppress the expression of MHC 
Class II in DCs (Harizi and Gualde, 2002).   
The ability of astrocytes to produce PGE2 in large quantities in response to 
inflammatory mediators is well documented. In vitro, astrocytes treated with IL-6, TNF-
α, IL-1β or LPS upregulate the expression of PGE2 whereas treatment with IL-10 or IL-4 








3.2 Interleukin-10 (IL-10) 
IL-10 was originally identified as a Th2-derived cytokine capable of inhibiting pro-
inflammatory cytokine synthesis by APC-stimulated Th1 cells (Fiorentino et al., 1991). 
IL-10 is the “founding member” of a super family of cytokines based on their similar 
genomic organization, structure of receptors and signaling pathways used. The IL-10 
super family includes IL-19, -20, -22, -24, -26, -28 and -29 (Conti et al., 2003). 
Appropriately stimulated immune and non-immune cell types including Th2, Th17, 
monocytes, macrophages, DCs, astrocytes, microglia, keratinocytes, epithelial cells and 
tumor cells can secrete IL-10 in significant quantities (Cheon et al., 2006; de Waal et al., 
1991; O'Garra and Murphy, 2009; Williams et al., 1996).  
Similar to other cytokines, IL-10 signaling uses the JAK/STAT pathway. The IL-
10 receptor (IL-10R) is a heterodimer composed of IL-10R1 and IL-10R2 subunits. IL-10 
ligation of its receptor activates the tyrosine kinases Jak1 and Tyk2, which induce the 
phosphorylation and activation of the downstream transcription factors STAT-1, -3 and -
5 (Gonzalez et al., 2009; Moore et al., 2001; Mosser and Zhang, 2008). 
 IL-10 modulates Th1 activity indirectly by mediating the maturation and function 
of DCs IL-10 can regulate almost every aspect of DC maturation/function.  It inhibits the 
expression of MHC Class II and the co-stimulatory molecules CD40, CD80 and CD86 on 
activated monocytes and isolated microglia and prevents their APC functions (Ding et al., 
1993; Ding and Shevach, 1992; Fiorentino et al., 1991; Frei et al., 1994; Kim et al., 2002; 
O'Garra and Murphy, 2009; O'Keefe et al., 1999; Qin et al., 2006; Taylor et al., 2006; 
Taylor et al., 2007; Wei and Jonakait, 1999). IL-10 also has the ability to inhibit the 







molecule (Bogdan et al., 1991; de Waal et al., 1991; Fiorentino et al., 1991; Harizi and 
Gualde, 2006; Heyen et al., 2000; Hu et al., 1999; Ledeboer et al., 2000; Wang et al., 
2000). A low amount of endogenous IL-10 produced by immature monocyte-derived 
DCs is a potent inhibitor of DC “spontaneous” maturation (Corinti et al., 2001). 
LPS treatment of isolated murine microglial cells in the presence of IL-10 leads to 
a reduction in the amount of CD40 expressed through the induction of the suppressor of 
cytokine signaling-3 (SOCS-3) gene mechanism (Qin et al., 2007). Similarly, IL-10 
prevents IFNγ-induced CD40 and MHC Class II expression (O'Keefe et al., 1999; Wei 
and Jonakait, 1999). Furthermore, IL-10 inhibits microglial expression of both cytokines 
and cytokine receptors. Microglia stimulated with LPS and IL-10 show a significant 
decrease in the amount of TNF-α, IL-6 and IL-1 secreted in addition to reducing the 
expression of receptors for IL-2 and IL-6 (Ledeboer et al., 2000; Sawada et al., 1999). 
Importantly, mixed glial cultures express IL-10 in biologically relevant quantities 
(Ledeboer et al., 2002). In their hands mixed glial cultures treated with LPS show a 
robust time-dependent increase in the amount of IL-10 secreted, with both astrocytes and 
microglia contributing to this increase. Interestingly, IL-10 has very little direct effect on 
mature T cells since the IL-10R is downregulated in activated T cells (Fiorentino et al., 
1991). However, stimulation of naïve T cells in the presence of IL-10 can result in anergy 
and death. It accomplishes this by interfering with the important secondary CD28-
CD80/86 signaling between DCs and naïve T cells (Taylor et al., 2007). Consistent with 
its role in immune-suppression, IL-10 deficient mice exhibit exacerbated symptoms of 







3.3 Transforming Growth Factor-β (TGF- β) 
TGF-β is a pleiotropic cytokine with diverse functions, and is a potent immunoregulator. 
There are three members in the TGF family: TGF-β 1, -2 and -3(DeGroot et al., 1999). 
Upon ligating TGF-β, the TGF-β type I receptor dimerizes with the type II TGF-β 
receptor which in turn induces the phosphorylation of the type I receptor. The activation 
of the receptor leads to phosphorylation of the receptor-SMADs (R-SMAD) transcription 
factors. Activated R-SMADs then recruit the common-SMAD (co-SMAD) and 
translocate into the nucleus to initiate gene transcription (Attisano and Wrana, 2002).  
 TGF-β can affect T cell function directly by influencing their proliferation, 
differentiation and survival (Chen et al., 2001b; Dardalhon et al., 2008; Fahlen et al., 
2005; Fontana et al., 1992; Ghoreschi et al., 2010; Gorelik and Flavell, 2002; Li and 
Flavell, 2008; Licona-Limon and Soldevila, 2007; Mangan et al., 2006; McGeachy et al., 
2007; Qin et al., 2009; Veldhoen et al., 2006; Wan and Flavell, 2006; Xu et al., 2002; 
Zheng et al., 2008; Zhou et al., 2008). It can also effect T cells by influencing the 
maturation and function of DCs (Borkowski et al., 1997; Coquerelle and Moser, 2008; 
Dong et al., 2001; Laouar et al., 2008; Manicassamy et al., 2010; O'Keefe et al., 1999; 
Pazmany et al., 2000; Wei and Jonakait, 1999; Xiao et al., 2002; Xu et al., 2002; 
Yamazaki et al., 2007). TGF-β signaling-deficient DCs are incapable of tolerizing T cells 
which results in spontaneous EAE-like disease with poor prognosis (Laouar et al., 2008). 
However, in a few scenarios TGF-β can serve to promote the differentiation and 
maturation of DCs. Langerhans cells (LCs), a sub-type of DCs present in the epidermis, 
absolutely require TGF-β1 for development as mice deficient in TGF-β1 expression do 







TGF-β also prevents the maturation of isolated microglia when stimulated with 
LPS or inflammatory cytokines (Kim et al., 2004; Lodge and Sriram, 1996; Paglinawan 
et al., 2003; Suzumura et al., 1993). It inhibits the expression of co-stimulatory molecules 
particularly of CD40, CD80, CD86 and MHC II (Lodge and Sriram, 1996; Wei and 
Jonakait, 1999). It also prevents microglia from expressing pro-inflammatory agents such 
as IL-12, nitrous oxide (NO), RANTES and further  induces the production of anti-
inflammatory products (Hu et al., 1999; Paglinawan et al., 2003; Vincent et al., 1998). 
Importantly for these studies, TGF-β is expressed in vitro by astrocytes and microglia in 
mixed glial cultures and in the healthy CNS in vivo (Dhandapani et al., 2003; Hailer et 
al., 1998; Logan et al., 1992). Thus, it is a prime candidate to be the astrocytically-
derived inhibitor of microglial activation. 
3.4 Rationale for the Current Studies 
This thesis investigates the nature of an astrocytic/microglial cross-talk that affects the 
ability of microglia to assume a DC-like phenotype. Furthermore, the ability of microglia 
cultured  in  the  presence or absence of  astrocytes to influence CD4
+
 T cell  proliferation  





MATERIALS AND METHODS 
4.1 Mice  
B10.A, and B6.129P-CX3R1
tm1Litt/J
 mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME) and bred at the Rutgers-Newark AAALAC-approved animal care 
facility. In order to obtain neonates for glial cultures, males and females were placed 
together for 5-7 days. 16-21 days thereafter, 1-3 day old pups were taken for glial 
cultures (see below).   
4.2 Reagents 
Recombinant mouse GM-CSF, rmIL-10 and rhTGF-β1 were purchased from Peprotech 
(Rocky Hill, NJ). Lipopolysaccharide (LPS;    055:B5) was from Sigma-Aldrich. Rabbit 
polyclonal antibodies against murine IL-10 and against all forms of TGF-β (pan-TGF ) 
were from R&D Systems (Minneapolis, MN). PE-conjugated Armenian hamster anti-
mouse CD11c monoclonal antibody (clone N418) and IgG isotype control antibodies and 
the IL-17A, IFN-γ, IL-4 and IL-10 ELISA kits were from BioLegend (San Diego, CA). 
Matrigel
TM
, purified rat anti-mouse CD3, rat anti-mouse CD28, FITC-conjugated 
monoclonal rat anti-mouse CD40 (IgG2A, ), Armenian hamster anti-mouse CD80 (IgG2, 
), rat anti-mouse CD86 (IgG2A, ), mouse anti-mouse MHC Class II antibodies (IgG2A, 
) and the appropriate isotype control antibodies along with Mouse Fc Block
TM
 were 
obtained from BD Biosciences (Franklin Lakes, NJ). Rabbit polyclonal antibodies against 






 inserts were from Corning (Lowell, MA). Anti-CD11c and anti-CD4 
magnetic beads were from Miltenyi Biotec (Sunnyvale, CA). PE-conjugated rat anti-
mouse/rat Foxp3 (IgG2A, ) and IgG isotype control antibodies were from eBioScience 
(San Diego, CA). ProstaglandinE2 is from Cayman Biologicals.  
4.3 Generation of Mixed Glial Cultures 
Mixed glial cultures were prepared as described previously from the cortices of neonatal 
(P1-P3) pups (Kreutzberg, 1995). Cortices were cleared of meninges, minced and 
triturated with a fire-polished Pasteur pipette and plated into poly-lysine-coated 75 cm
2
 
flasks in medium containing D-MEM/F12 (1:1), penicillin (25 U/ml), streptomycin (25 
μg/ml), D-glucose (0.6%), and 10% heat-inactivated fetal bovine serum (BioAtlantic). 
Medium was replaced on day 3 and half the medium exchanged every 3 days thereafter. 
Isolated microglial cultures were generated by shaking microglia off of 12-14-day old 
mixed glial cultures on an orbital shaker (250 RPM X 15-20 min). Floating cells were 
collected and plated onto uncoated 75mm
2
 flasks and allowed to adhere to the substrate 
before being treated with GM-CSF and LPS (see diagram below). 
Unless stated otherwise, both mixed glial and isolated microglial cultures were 
treated with rmGM-CSF (25ng/ml) for 5 days and LPS (50ng/ml) for an additional 2 days 




Figure 4.3 A diagram of the treatment protocol. 
4.4 Generation and Purification of BM-DCs 
Bone marrow (BM) cells were flushed with ice-cold RPMI medium from the femurs of 
12-16 week old B10.A mice. BM cells were cultured in 100-mm Petri dishes containing 
10 mL RPMI 1640 medium supplemented with 10% heat-inactivated FBS (BioAtlantic), 
2 mM L-glutamine, penicillin (25 U/ml), streptomycin (25 μg/ml), 50 μM beta-
mercaptoethanol (BME) and 15 ng/mL recombinant GM-CSF. After 3 days floating cells 
were harvested, pelleted and plated onto 75cm
2
 flasks with or without enriched astrocytes 
(see below) in fresh RPMI medium containing GM-CSF (15 ng/ml). LPS (50 ng/ml) was 
added for 48 hrs on the 5
th
 day of GM-CSF treatment. For experiments involving CD11c
+
 
purified BM precursors, BM precursors were purified by CD11c immunomagnetic 
sorting using the AutoMACS
TM
 system (Miltenyi Biotec). CD11c
+
 cells were plated into 
75cm
2
 flasks and treated with GM-CSF and LPS as described above. The purity of the 
sorted cells was determined by flow cytometric analysis ( >97% for CD11c
+
 cells). 
4.5 Generation of Enriched Astrocytic Cultures 
Enriched astrocyte cultures were prepared from mixed glial cultures from which 
microglia had been shaken off. Following the removal of loosely adherent microglia, 
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They were passaged 2-3 times by light trypsinization (0.2% trypsin) followed by washing 
and replating into poly-lysine-coated flasks. Thus processed, they are >95% pure as 
defined by staining of microglial contaminants with antibodies against CD11b. 
4.6 T cell Isolation and Culture 
CD4
+
 T cells were isolated and purified by positive selection from spleens of B10.A mice 
(I-E
k
) using the AutoMACS™ System. These were cultured in 48 well plates either alone 
or with microglia taken from the two culture settings in a microglia:T cell ratio of 1:10. 
Cells were plated in medium containing RPMI 1640, BME (10 µM), 10% FCS, penicillin 
(25 U/ml) and streptomycin (25 µg/ml) in the presence and absence of antibodies against 
CD3 (1.0 µg/ml, BD Biosciences). After 3 days, T cells were harvested and prepared for 
analysis by flow cytometry and determination of cytokines by ELISA. Mixed glia were 
stimulated with GM-CSF for 5 days followed by LPS for 2 days. Microglia were then 
shaken off and replated with CD4
+
 T cells or were reseeded with CD4
+
 T cells onto a bed 
of enriched astrocytes previously treated with GM-CSF and LPS.  
For analysis of regulatory T cells, T cells were fixed and permeabilized with 
Foxp3 Fixation/Permeabilization Concentrate and Diluent (eBioscience) before being 
stained with PE-conjugated rat anti-mouse antibodies against Foxp3 (eBioscience, 
0.5µg). Isotype control antibodies were handled similarly.  
T cell proliferaton was determined in a T cell activation assay using CD4
+
 B10.A 
T cells on B10.A glia that had been previously treated with GM-CSF and LPS as 
described above. In all cases, T cells were labeled with 5 µM carboxyfluorescein 
diacetate succinimidyl ester (CFSE; Molecular Probes, CA) prior to plating with 




4.7 Flow Cytometric Analysis 
Microglial cells were shaken off of the mixed glial cultures or gently lifted off the 
isolated microglial cultures with a “cell lifter.” Cells were pelleted and re-suspended in 
phosphate buffered saline (PBS) containing 2% fetal bovine serum. Cells were then 
stained with PE-conjugated anti-CD11c and FITC-conjugated CD40, CD80, CD86 or 
MHC Class II or the appropriate IgG isotype control for 1 hour on ice. To minimize non-
specific staining, cells were incubated with Fc Block™ (BD Bioscience) according to 
manufacturer’s instructions. After incubation cells were washed twice and resuspended in 
the same buffer before being assayed on a FACSCalibur flow cytometer (BD, 
Mountainview, CA). Data analysis was accomplished using CellQuest® software. Gating 
was done by using the appropriate isotype controls as reference. Non-specific staining for 
each experimental group was assessed through staining by isotype controls and was 
excluded from analysis by only counting events that were not a part of the isotype 
controls.  
4.8 Real-time PCR 
Total microglial RNA was prepared using Ultraspec™ RNA Isolation Reagent (Biotecx 
Laboratories, Inc., Houston, TX). cDNA was produced from 1μg of RNA by using 
random hexamer and MMLV reverse transcriptase (Promega, Madison, WI) according to 
the manufacturer’s instruction. The primers used for real-time PCR were obtained from 
Integrated DNA Technologies, Inc. (Coralville, IA) and were designed using Primer 
Express (Applied Biosystem, Foster City, CA). They are listed in Table 4.1. For real-time 
PCR, cDNA was amplified using the SYBR Green PCR Master Mix (Applied 




were 10 minutes at 95
º
C, followed by 35 cycles of 15 seconds at 95
º
C and 15 seconds at 
60
º





(each for 15 seconds) was used for a dissociation curve to verify that the signal is 
generated from a single target amplicon and not from primer dimers or contaminating 
DNA. Serially diluted cDNA of each sample was amplified to measure the efficiencies of 
PCR and to draw the standard curve for each sample to calculate relative concentration of 
target message. The PCR products and their dissociation curves were detected using the 
ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA).  






5’-CTG CCC AGT CGG CTT CTT CTC-3’ 
5’-CCT GTG TGA CAG GCT GAC AC-3’ 
CD80 F 
R 
5’-CTG GGA AAA ACC CCC AGA AG-3’ 
5’-TGA GAA CGA TGA CGA CGA CTG-3’ 
CD86 F 
R 
5’-TTA GGG AAG CAC CCA TGA TG-3’ 
5’-CGT CTC CAC GGA AAC AGC AT-3’ 
MHC CLASS II F 
R 
5’-CAA CAC TCT GGT CTG CTC AGT GA-3’ 
5’-TGT GTG GAT GAG ACC CCC A-3’ 
4.9 ELISAs 
Supernatants were collected from T cells cultured in the presence of microglia from 
various culture settings. IL-17A was estimated using sandwich ELISA kits from 
Biolegend according to manufacturers’ instructions. Both capture and biotinylated 
detection antibodies for measuring interferon-gamma (IFN- ), interleukin-4 (IL-4) and 
IL-10 were from BDPharmingen. For IFN- , the capture antibody was purified 
monoclonal anti-mouse IFN-  (3.5 g/ml);     the biotinylated detection antibody was 




capture antibody was rat anti-mouse (3 g/ml);     the detection antibody was used at 1.5 
g/ml. The detection limits of the assay were 7.8-2,000 pg/ml. For IL-10, the capture 
antibody was a monoclonal anti-mouse (3 g/ml); the detection antibody was used at 1.5 
g/ml. The detection limits of the assay were 7.8-2,000 pg/ml. Optical density (OD) of 
standards and samples was measured using an ELISA plate reader (Packard Biosciences). 
Standard curves were generated for each assay and sample concentrations were obtained 
from the standard curve by comparing OD of samples to that of standards. Samples were 
assayed in triplicate and compared using an ANOVA with a post-hoc Student-Newman-








Specific Aim 1. To determine the effect of astrocytes on the ability of microglia to 
express dendritic cell (DC) markers CD11c, MHC Class II and co-stimulatory molecules 
CD40, CD80 and CD86.  
5.1 Astrocytes Modulate the Maturation of Microglial Cells 
 into a Dendritic Cell-like Phenotype 
 
The sequential treatment of isolated microglia with GM-CSF and LPS has been shown by 
us and others to induce a program of transcription that culminates in the generation of 
microglia with a DC-like phenotype (Aloisi et al., 2000; Ponomarev et al., 2007). 
However, most if not all studies to-date have dealt with microglia in isolation, and there 
is a dearth of research investigating microglial interactions with other cells commonly 
found throughout the CNS, especially astrocytes. To investigate the effect of astrocytes 
on the induction of a microglial DC-like phenotype, isolated microglia (labeled “OFF”) 
and mixed glial cultures (labeled “ON”) were sequentially treated with GM-CSF and LPS 
(see Materials and Methods) and the simultaneous expression of the DC marker CD11c 
and co-stimulatory molecules CD40, CD80, CD86 or MHC Class II assessed by flow 
cytometry.  
Compared to microglia in the presence of astrocytes, a significantly higher 
percentage of isolated microglia expressed the DC marker CD11c (73.4 
+ 
4.2 % [OFF] vs. 
41.9 
+ 




simultaneously expressing CD11c and CD40, CD80, or CD86 was also significantly 
higher than microglia cultured in the presence of astrocytes (Figures 5.1A and B). 
However, there was no significant difference in the percentage of microglia expressing 
CD11c and MHC Class II in the different environments (Figure 5.1B). While the 
percentages of cells expressing DC markers was strikingly different, the mean 
fluorescence index (MFI), a measure of the number of molecules per cell, shows that only 
CD40 differs significantly between the two culture conditions (Figure 5.1C).   
The kinetics of CD11c and CD40 expression after the addition of LPS was 
examined to further distinguish between isolated microglia and microglia cultured on 
astrocytes. The percentage of co-cultured microglia expressing CD11c and CD40 
increases in a time-dependent manner following the addition of LPS, while the 
percentage of isolated microglia expressing CD11c and CD40 remains unchanged (Figure 
5.1D) suggesting that it had reached maximum levels with the treatment of GM-CSF 
alone.  
To ensure that astrocytes were the only cells affecting the phenotype of the 
microglia, microglia from mixed glial cultures were purified through CD11b magnetic 
cell sorting and plated onto an enriched culture of astrocytes prepared as described above 
in Materials and Methods. Other microglia remained with a more heterogeneous 
population of mixed glia. Following treatment with GM-CSF and LPS, microglia from 
both settings were assessed for CD11c and CD40 expression. The percentage of CD11b
+
 
enriched microglia that expressed CD11c and CD40 on enriched astrocytes is lower than 
microglia cultured in a more heterogeneous environment. These data, along with Figure 










































Figure 5.1  Astrocytes inhibit microglial production of a mature DC phenotype. 
Microglia were cultured with GM-CSF (25 ng/ml) in the presence (ON) or absence 
(OFF) of astrocytes for 5 days. LPS (50 ng/ml) was added for an additional two days. 
(Continued on page 57.)   








































































































































Co-stimulatory molecule surface expression was determined by flow cytometry (A and 
B). Numbers in the upper right quadrants represent the percentage of CD11c
+
 cells 
simultaneously positive for CD40, CD80, CD86 and MHC Class II respectively. 
 (B) Microglial surface expression of co-stimulatory molecules in isolation is 
significantly higher than those on microglia cultured with astrocytes. Data are expressed 
as the percentage of cells expressing both CD11c and another co-stimulatory molecule 
+
 
SEM over three individual experiments. Data from isolated and co-cultured microglia 
were compared by a Student’s t-test. An asterisk indicates p<0.05. (C) Only microglial 
CD40 Mean Fluorescence Intensity (MFI) differs in the presence (ON) and absence 
(OFF) of astrocytes. Data are expressed as the MFI 
+
 SEM and compared by a Student’s 
t-test. The asterisk indicates p<0.05. (D) Percentage of co-cultured (ON) microglia 
simultaneously expressing CD11c and CD40 increases over the course of 48 hours. 
Microglia were treated with GM-CSF (25 ng/ml) in the presence (ON) or absence (OFF) 
of astrocytes for 5 days. LPS (50 ng/ml) was added and cells were harvested at various 
time points after the addition of LPS and examined by flow cytometry for the expression 
of CD11c and CD40. The data are representative of two experiments performed. (E) 
Fewer CD11b
+
 enriched microglia cultured in the presence of astrocytes express CD11c 
and CD40 compared to microglia cultured in a more heterogeneous population. This 
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5.2 Microglia in the Presence of Astrocytes Express Higher Levels  
of Co-stimulatory Molecule mRNA 
Because isolated microglia express higher surface levels of co-stimulatory molecules than 
their co-cultured counterparts, the temporal expression of these molecules following LPS 
treatment was assessed using RT-PCR (Figure 5.2A-D). In microglia co-cultured with 
astrocytes mRNA levels for CD40, CD80 and CD86 increased rapidly, peaking at 3 hrs 
and declining thereafter. By contrast, MHC Class II mRNA levels rose slowly but 
steadily reaching highest levels at the 12 hr time point. In the isolated microglia, CD40, 
CD80, CD86 and MHC Class II expression showed a similar temporal pattern. However, 
at all time points examined, steady-state mRNA levels in isolated microglia were 
significantly lower than those of co-cultured microglia. In the case of CD86 and MHC 
Class II, these levels were strikingly lower. Because mRNA levels rose rapidly following 
LPS treatment, it was clear that microglia -- even in the presence of astrocytes -- were 
responsive to LPS signaling. 
 Unexpectedly, the mRNAs for various “housekeeping” genes such as GAPDH, 
ARP and HTRP1 also showed significant differences between the two culture conditions 
(data not shown) making standardization to a housekeeping gene impossible. Figure 5.2  
































Figure 5.2   RT-PCR analysis of microglial expression of mRNA for MHC Class II and 
co-stimulatory molecules following a 24-hr LPS time course. Microglia in the presence 
of astrocytes (ON) or in their absence (OFF) were treated with GM-CSF (25ng/ml) for 5 
days and LPS (50ng/ml). Microglia were harvested at various time points indicated after 
LPS addition and (A) CD40 (B) CD80 (C) CD86 (D) MHC class II mRNA expression 
assessed through real-time PCR. The data are expressed as arbitrary units 
+
 SEM from 3 
separate experiments. Levels at each time point were compared by a Student’s t-test. The 
asterisk indicates p<0.05.  
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5.3 Astrocytes Prevent the Efficient Maturation of Bone Marrow-derived  
DC (BM-DC) Precursor Cells into Fully Mature DCs. 
BM-DCs are considered to be professional APCs of the immune system and are a vital 
component of the adaptive immune response. To investigate the effect of astrocytes on 
the maturation of BM-DC precursor cells, precursors were extracted and cultured in the 
presence of GM-CSF (15-20 ng/ml) for three days in isolation. After three days, floating 
cells were collected and either plated onto enriched astrocytic cultures or cultured alone 
and treated with GM-CSF for a further 5 days and LPS (50 ng/ml) for an additional 2 
days to induce maturation. BM-DC precursors cultured alone expressed robust levels of 
co-stimulatory markers as measured by flow cytometry (Figure 5.3A and B). By contrast, 
BM-DCs in the presence of astrocytes expressed significantly lower levels of  CD11c and 
CD40, CD80 or CD86. Similar to microglia, the percentage of BM-DCs simultaneously 
expressing CD11c and MHC Class II was the same in both conditions (Figure 5.3B).    
Bone marrow cells are a heterogeneous mix of assorted precursor cells as well as 
cells at various stages of maturation. Thus, in order to ensure that the results observed 
were due solely to an interaction between BM-DCs and astrocytes alone CD11c
+
 cells 
were isolated through magnetic cell sorting prior to placement onto astrocytes. Before 
purification, 35% of the precursor cells were CD11c
+
;     after purification, the percentage 
of CD11c
+
 cells rose to 97% (Figure 5.3C). Purified CD11c
+
 BM cells in the presence or 
absence of astrocytes were then treated as described above and the percentage of cells 
expressing CD11c and CD40 or CD80 was ascertained by flow cytometry. As observed 







compared to BM-DCs in the presence astrocytes (35.4% vs. 62.2% and 19.8% vs. 54.5%) 













Figure 5.3  Astrocytes inhibit the expression of a mature DC phenotype in bone marrow-
derived cells. BM precursors were obtained from the femurs of B10.A mice and cultured 
for 3 days in the presence of GM-CSF (25 ng/ml). Floating cells were collected and 
treated with GM-CSF (25 ng/ml) for 5 days and LPS (50 ng/ml) for an additional 2 days 
in the presence (ON) or absence (OFF) of astrocytes. (A) CD11c and co-stimulatory 
molecule surface expression was determined by flow cytometry. Numbers in the upper 
right quadrants represent the percentage of CD11c
+
 cells simultaneously positive for 
CD40, CD80, CD86 and MHC Class II respectively. (B) BM-DC surface expression of 
co-stimulatory molecules in isolation is significantly higher than those on BM-DCs 
cultured with astrocytes. Data are expressed as the percentage of cells expressing both 
CD11c and another co-stimulatory molecule 
+
 SEM over 3 individual experiments. Data 
from isolated and co-cultured BM-DCs were compared by a Student’s t-test. An asterisk 
indicates p<0.05. A higher percentage of purified CD11c
+
 cells cultured in the presence 
of astrocytes show surface expression of CD40 and CD80.  









































(C) Selection of CD11c
+
 cells by magnetic cell sorting from bone marrow cells yielded 
an almost pure population of cells. (D) Purified CD11c
+
 BM precursors were treated with 
GM-CSF (25 ng/ml) for 5 days and LPS (50 ng/ml) for two more days in the presence 
(ON) or absence (OFF) of astrocytes. Cells were then analyzed for CD11c and CD40 or 
CD80. Numbers in the upper right corner represent the percentage of cells expressing 
CD11c and CD40 or CD80. Fewer CD11c
+
 enriched BM precursors cultured in the 
presence or absence of astrocytes express CD11c and CD40 or CD11c and CD80 





























5.4 Astrocytes Preserve the Expression of the Fractalkine 
 Receptor (CX3CR1) on Microglia 
 
Fractalkine is a 373 amino-acid chemokine that is widely expressed in the CNS (Bazan et 
al., 1997; Chinnery et al., 2007; Rossi et al., 1998). It is constitutively expressed by 
neurons whereas astrocytes can be induced to express it in the presence of pro-
inflammatory stimuli (Harrison et al., 1998; Hatori et al., 2002). It can exist as a 
membrane bound molecule or -- when proteolytically cleaved -- as a soluble 90 kD 
isoform (Hatori et al., 2002). CX3CR1, the receptor for fractalkine, is expressed 
throughout the body by various cell types;     among them are monocytes, DCs and T 
cells (Jung et al., 2000). Microglia are the only cell type in the CNS to express the 
fractalkine receptor (Hatori et al., 2002), and as a result, microglia respond to fractalkine 
by converging towards its source (Tarozzo et al., 2002). In addition to its chemotactic 
properties, fractalkine, by inhibiting microglial activation, can promote neuronal survival. 
In vitro, microglia activated with LPS in the presence of fractalkine down-regulate the 
expression of pro-inflammatory mediators detrimental to neuronal survival (Mizuno et 
al., 2003; Zujovic et al., 2000). While LPS-treated isolated monocytes and microglia 
down-regulate the expression of CX3CR1 (Boddeke et al., 1999; Ramos et al., 2010) 
little else is known about the regulation of the receptor on microglia.  
To determine the effect of astrocytes on microglial expression of CX3CR1, mixed 
glial cultures were obtained from neonatal B6.129P-Cx3cr1
tm1Litt
/J mice. In these 
transgenic mice, GFP has been placed under the control of the CX3CR1 promoter and is 
expressed instead of the fractalkine receptor in all cells derived from a monocytic lineage 
(Jung et al., 2000). This allows not only the identification of microglia but also allows 
measurement of their expression of CX3CR1
GFP/GFP




LPS a significantly higher percentage of microglia in the presence of astrocytes retain 
their expression of CX3CR1
GFP/GFP
 compared to microglia cultured alone (Figure 5.4A) a 
fact confirmed by immunohistochemistry (Figure 5.4B). The mere withdrawal of 
microglia from an astrocytic environment is sufficient to induce the down-regulation of 
CX3CR1. A high percentage (~56%) of microglia 48 hours after isolation from astrocytes 
and in the absence of any exogenously added ligands do not express GFP whereas more 
than 95% of freshly isolated microglia are GFP positive (Figure 5.4C). Taken together 
these data show the importance of an astrocytic environment for the expression of 
microglial CX3CR1. 
Because of the dramatic decrease in GFP expression, the experiment was repeated 
on wild-type C57Bl/6J animals using a antibody against CX3CR1. After 48 hrs, 53% 
(n=2) of isolated microglia retained cell surface expression of CX3CR1 (Not shown). 
































Figure 5.4 Astrocytes preserve microglial CX3CR1
GFP/GFP 
expression. Mixed glial 
cultures were obtained from neonatal B6.129P-CX3R1
tm1Litt/J
 transgenic mice. 
CX3CR1
GFP/GFP
 microglia were cultured with GM-CSF (25 ng/ml) in the presence (ON) 
or absence (OFF) of astrocytes for 5 days. LPS (50 ng/ml) was added for an additional 
two days. CD11c and GFP expression was determined by flow cytometry. (A) A higher 
percentage of microglia in the presence of astrocytes are CX3CR1
GFP/GFP
 positive than 
microglia cultured in isolation. The figure is representative of data replicated 4 times. (B) 
Isolation of microglia from astrocytes leads to a decrease in CX3CR1
GFP/GFP
 expression. 
Microglia were cultured in isolation for 48 hours in the absence of any exogenously 
added ligands. CX3CR1
GFP/GFP
 expression was examined by flow cytometry. Numbers in 
the quadrants indicate the percentage of microglia expressing GFP. This experiment was 
performed once. (C) Removal of microglia from an astrocytic environment leads to a loss 
of microglial GFP expression. “ON” and “OFF” microglia were examined by by 
fluorescence microscopy for GFP expression. Microglia were cultured in the presence or 
absence of astrocytes and treated with GM-CSF (25ng/ml, 5 days) and LPS (50ng/ml, 2 
days). Microglia with astrocytes (+Astrocytes) or in isolation (- Astrocytes) were fixed, 








Specific Aim 1. To determine whether differences in surface expression of these DC-
specific molecules was the result of soluble or contact-mediated events. 
Conclusions from Specific Aim 1:  
 
In the presence of astrocytes: 
 
 a significantly smaller percentage of microglia express CD11c together with co-
stimulatory molecules CD40, CD80 and CD86, molecules necessary for T cell 
activation;      
 
 microglial mRNA for CD40, CD80 and CD86 and MHC Class II is significantly 
higher than in isolated microglia;     
 
 a significantly smaller percentage of bone marrow-derived DCs express CD11c 
together with co-stimulatory molecules CD40, CD80 and CD86;     
  
 neither microglial nor BMDC MHC Class II surface expression differs from that 
seen in isolated cells;     
  




Specific Aim 2: To determine whether differences in surface expression of these DC-
specific molecules is the result of soluble or contact-mediated events. 
5.5 Neither PGE2, IL-10 nor TGF-  Mediate Microglial Suppression 
Several anti-inflammatory cytokines -- PGE2, IL-10 or TGF-β -- produced by astrocytes 
were examined as possible mediators of microglial suppression. Data from the Jonakait 
lab and from others (Levi et al., 1998) suggest that the addition of PGE2 to isolated 
microglial inhibits the expression of CD40 (Figure 5.5A and B). In addition, the data here 
and that of others (Kim et al., 2002; Qin et al., 2006) suggested that IL-10 is significantly 
elevated in the mixed glial cultures (Figure 5.5D). Others have pointed to TGF  as a 
highly anti-inflammatory molecule (Paglinawan et al., 2003; Wei and Jonakait, 1999). 
These three molecules were, therefore, selected as likely soluble mediators of the 
microglial suppression. To test the effect of these factors on isolated or mixed glial 
cultures, they were either exogenously supplied or their endogenous activity neutralized 
through specific antibodies.   
In order to determine whether PGE2 qualified as a glial-derived factor responsible 
for suppressing co-stimulatory molecule expression, it was added to isolated microglial 
and mixed glial cultures in a concentration (10 M) shown to suppress CD40 expression 
in isolated cultures (Figure 5.5B). With the exception of MHC Class II, the percentage of 
isolated microglia expressing CD11c and the other co-stimulatory molecules was 
suppressed by PGE2 (Figure 5.5C). By contrast, addition of PGE2 to mixed glial cultures 




II. CD86 remained unchanged (Figure 5.5C). These data suggest that PGE2 is not the 
mediator of microglial suppression in the presence of mixed glia. 
The addition of IL-10 to isolated microglia did not lower the percentage of cells 





 cells even with increasing concentrations of IL-10 (assessed 
by an ANOVA; p=.701).  Moreover, a neutralizing antibody against IL-10 that was used 
to counteract the high levels of endogenous IL-10 in the mixed glial cultures did not 





 cells even with increasing concentrations of the antibody 
(assessed by an ANOVA; p=.786). If IL-10 were the mediator, this antibody would be 
expected to raise the percentage of cells expressing CD11c and CD40 particularly in the 





 microglia in either culture condition (Figure 5.5G). IL-10 failed to 
meet the requirement for an appropriate mediator.   
Next, the effect of TGF-β was examined on both “ON” and “OFF” microglia. 
rhTGF-β1 added to isolated microglia increased the percentage of microglia co-
expressing CD11c and CD40 while significantly reducing that expression in a mixed glial 
environment (Figure 5.5H). Moreover, TGF-β1 exerted its effect on mixed glia even at 
the relatively low concentration of 10 ng/ml. In order to determine whether endogenous 
TGF-  was responsible for the observed effect of astrocytes on inhibiting CD40, 
endogenous TGF-  was neutralized using a pan-anti-TGF-β antibody. This particular 
antibody efficiently neutralizes most of the common isoforms of TGF-β (R&D Systems). 








 microglia in the mixed glial condition (Figure 5.5I). The 





in either culture condition (Figure 5.5J). Had TGF-  been the mediator of suppression, 
the addition of the antibody would have been expected to reverse the suppression. 
Because this did not happen, TGF-  was eliminated as a possible mediator.  
Taken together, these data show that neither PGE2, IL-10 nor TGF-β is the 
astrocytic mediator responsible for suppressing microglial activation in a mixed glial 
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Figure 5.5  PGE2 treatment downregulates CD40 mRNA expression in isolated 
microglia. (A) Isolated microglia were treated with LPS and increasing doses of PGE2 
and the expression of CD40 mRNA determined by RT-PCR. (B) The percentage of 
isolated microglia expressing CD40 and CD11c is significantly reduced in the presence 
of PGE2. Isolated microglia were treated with GM-CSF (25 ng/ml, 5 days) and LPS (50 
ng/ml , 2 days). PGE2 was added in increasing doses before and 24 hrs after the addition 
of LPS. Microglia were collected and the expression of CD11c and CD40 determined by 




 cells + SEM (n=3 or more). An 
asterisk represents a difference with PGE2 untreated control (*p<.05). (C) PGE2 is not 
the mediator of astrocytic action. ON and OFF microglia were treated with GM-CSF (25 
ng/ml, 5 days) and LPS (50  ng/ml , 2 days). PGE2 (10µM) was added before and 24 hrs 
after the addition of LPS. Microglia were collected and the expression of CD11c and 
CD40 or CD80 or CD86 or MHC II determined by flow cytometry. 











































































(D) Mixed glial cultures produce higher amounts of IL-10. Mixed glial and isolated 
microglial cultures were treated with GM-CSF (25 ng/ml, 5 days) and LPS (50 ng/ml, 2 
days) and supernatants collected at the indicated times after the addition of LPS. The 
concentrations of IL-10 were determined by an ELISA. IL-10 is not the mediator of 
astrocytic action. ON and OFF microglia were treated with GM-CSF (25 ng/ml, 5 days) 
and LPS (50 ng/ml , 2 days). Data are expressed as pg/ml + SEM from triplicate samples. 
Asterisk indicates a significant difference of “ON” vs. “OFF” at each time point (p<0.05). 
One of two experiments is shown. 
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 (E) IL-10 was added at varying doses before and 24 hrs after the addition of LPS to 
isolated and mixed glial cultures. CD11c and CD40 were determined by flow cytometry. 
An ANOVA showed the addition of IL-10 did not significantly alter the percentage of 
cells expressing CD11c and CD40 in isolated microglia (p=0.701) (F) Neutralizing 
antibodies for IL-10 were added at varying doses before and 24 hrs after the addition of 
LPS to isolated and mixed glial cultures. CD11c and CD40 were determined by flow 
cytometry. An ANOVA showed that the addition of the antibodies did not significantly 
alter the percentage of cells expressing CD11c and CD40 in co-cultured microglia 
(p=0.786). (G) A control IgG control had no effect. (H) Microglia in both culture settings 
were treated with GM-CSF (25 ng/ml, 5 days) and LPS (50 ng/ml, 2 days). TGF-β was 
added at 10 ng/ml before and 24 hrs after the addition of LPS to isolated and mixed glial 
cultures. Microglia were collected and the expression of CD11c and CD40 determined by 




 cells + SEM. An 
asterisk represents a difference from TGF- -untreated co-cultured (ON) microglia 
(p=0.02, n=3). (I) Microglia in both culture settings were treated with GM-CSF (25 
ng/ml, 5 days) and LPS (50 ng/ml, 2 days). Pan-antibodies against all forms of TGF  
were added at varying doses before and 24 hrs after the addition of LPS to isolated and 
mixed glial cultures. Microglia were collected and the expression of CD11c and CD40 
determined by flow cytometry. This experiment was performed once. (J) A control IgG 





































































































































5.6 Repression of Microglial Activation and Maintenance of Microglial CX3CR1 
Requires Continued Contact with an Astrocytic Environment. 
 
In order to determine whether soluble astrocytic molecule(s) were responsible for the 
repression of microglial activation and maintenance of CX3CR1, microglia were cultured 
over astrocytes in a Transwell™ chamber. This design allows the two cell types to share 
any soluble factors while preventing the two cell types from coming into contact. Mixed 
glial cultures were plated onto 6 well plates and isolated microglia onto Transwell™ 
inserts (0.4 m pore size) before being treated with GM-CSF and LPS. Microglia thus 
separated from astrocytes but in contact with soluble factors coming from them failed to 
mimic the repressed DC-like phenotype typical of “ON” microglia. Instead, “transwell” 
microglia closely resembled their isolated counterparts (Figure 5.6A).  
Similarly, microglial maintenance of CX3CR1 also requires physical contact with 
astrocytes since microglia in the Transwell™ inserts lose their CX3CR1
GFP/GFP
 
expression after being treated with GM-CSF and LPS (Figure 5.6B). To further clarify 
the mode of astrocytic action, CX3CR1
GFP/GFP
 microglia were cultured in isolation, in the 
presence of GM-CSF. After 5 days, microglia were trypsinized and plated onto a 
confluent bed of enriched wild-type astrocytes and cultured for a further 2 days before 
being assessed for CX3CR1
GFP/GFP
 expression. Thus treated, ~37% of microglia recover 
their expression of CX3CR1
GFP/GFP
 when compared to microglia grown in isolation 
(Figure 5.6C). Taken together these data effectively eliminate most soluble factors as the 
astrocyte-derived mediators of microglial activity and suggest that contact with the 













Figure 5.6  Contact with the astrocytic environment is necessary for astrocytes to 
modulate microglial DC maturation. (A) B10.A microglia in the presence of astrocytes 
(ON) or absence of astrocyte (OFF) and microglia separated from mixed glial cultures 
with a Transwell™ apparatus (Transwell) were treated with GM-CSF (25 ng/ml, 5 days) 
and LPS (50 ng/ml, 2 days). Surface expression of CD11c and CD40 were assayed by 
flow cytometry. Representative data from one of two experiments are shown. (B) Cell 
contact with the astrocytic environment is required for CX3CR1
GFP/GFP
 microglia to retain 
GFP expression. CX3CR1
GFP/GFP
 microglia cultured with astrocytes (ON, black), without 
astrocytes (OFF, pink) or separated from mixed glial cultures with a Transwell™ 
apparatus (Transwell, blue) were treated with GM-CSF (25 ng/ml, 5 days) and LPS (50 
ng/ml, 2 days) and assessed for GFP expression by flow cytometry. Control (green line) 
represents wild-type cells used to compensate for auto-fluorescence. (C) CX3CR1
GFP/GFP 
microglia recover their GFP expression after being replated onto astrocytes. 
CX3CR1
GFP/GFP
 microglia were isolated from astrocytes and cultured with GM-CSF 
(25ng/ml) for 5 days. Microglia were then harvested by gentle trypsinization and plated 
onto a bed of wild-type enriched astrocytes, cultured for an additional 2 days and GFP 
expression measured by flow cytometry. Numbers above the histogram represent the 











5.7 Astrocytic Extracellular Matrix Molecules may Play a Role in Suppressing 
Microglial Expression of Co-stimulatory Molecules. 
 
Astrocytes express a wide variety of molecules which are involved in forming the extra 
cellular matrix (ECM). To further clarify the nature of the astrocytic membrane-bound 
molecule, microglia were cultured in the presence of Matrigel
TM
, a heterogeneous 
mixture of various extracellular matrix proteins, primarily laminin and collagen IV (BD 
Biosciences). It can be induced to form a 3D gel on plastic and has been shown by 
various studies to significantly affect cell behavior (Kleinman and Martin, 2005). To 
examine the effect of Matrigel
TM
 on microglial activation, isolated microglia were treated 
with GM-CSF and LPS in flasks coated with Matrigel
TM
. The expression of CD11c and 
CD40 was assessed after treatment with GM-CSF and LPS. Compared to microglia 
cultured in isolation, there is only a minor difference in the percentage of microglia 
expressing CD11c and CD40 in the presence of Matrigel
TM
 (Figure 5.7A). However, 
when compared to isolated microglia the amount of surface CD40 (as assessed by MFI) 
expressed per cell is lower in microglia cultured in the presence of Matrigel
TM
 (Figure 
5.7A).   
 Microglia derived from CX3CR1
GFP/GFP 
mixed glial cultures were similarly 




microglia retain their 
expression of GFP to a large extent when cultured on Matrigel
TM
 (Figure 5.7B). These 
data suggest that in addition to astrocytic membrane-bound molecules, the ECM secreted 
by astrocytes may also play a role in mediating the suppression of microglial activation. 









































 partially mimics the effect of astrocytes on microglia. (A) B10.A 
microglia in the presence of astrocytes (ON), isolated from astrocytes (OFF) and in the 
presence of Matrigel
TM
 (OFF+Matrigel) were treated with GM-CSF (25 ng/ml, 5 days) 
and LPS (50 ng/ml, 2 days) and assessed for the expression of CD11c and CD40 by flow 





microglia. MFI is mean florescence intensity. This experiment was performed once. (B) 
A higher percentage of isolated CX3CR1
GFP/GFP 
microglia retain GFP expression in the 
presence of Matrigel
TM
.  Microglia derived from CX3CR1
GFP/GFP
 mice were treated with 
GM-CSF (25 ng/ml, 5 days) and LPS (50 ng/ml, 2 days)  in the presence (ON) or absence 
of astrocytes (OFF) or on Matrigel
TM
 (OFF+Matrigel). Microglial GFP was assessed at 
the end of the treatment by flow cytometry. Numbers above the histogram indicate the 
percentage of GFP
+
 microglia.  






Specific Aim 2. To determine whether differences in surface expression of these DC-
specific molecules is the result of soluble or contact-mediated events. 
Conclusions from Specific Aim 2: 
 Neither PGE2, IL-10 nor TGF  is responsible for the astrocytic effect on 
microglial DC phenotype. 
 
 Contact with the astrocytic environment is required for astrocytic inhibition of the 





































Specific Aim 3: To examine the effects of differences in surface expression of these DC-
specific molecules on T cell proliferation, Foxp3 expression and cytokine production. 
 
5.8 A Mixed Glial Environment is More Conducive for 
T cell Activation and Proliferation 
 
The data so far reveal that microglia and BM-DCs in the presence of astrocytes are not as 
efficient as either cell type alone in upregulating the DC marker CD11c or the co-
stimulatory molecules CD40, CD80, and CD86 required for T cell activation and 
stimulation. To functionally differentiate between mixed and isolated microglial cultures, 
their ability to promote CD4
+
 T cell proliferation was ascertained. As described earlier, T 
cells require a primary signal provided by the T cell receptor and a co-stimulatory signal 
for proper activation. Here, the T cell receptor is stimulated through the addition of an  
exogenous CD3 antibody whereas the secondary signal is provided by the microglia with 
or without astrocytes or by the addition of exogenous CD28 antibody (αCD28). The 
optimal concentration of stimulatory CD3 antibody was determined to be 1 g/ml (Figure 
5.8A). Due to the presence of a confluent bed of astrocytes, plate-bound anti-CD3 
antibody could not be used (as is standard) to stimulate the T cells. Therefore, potential 
differences in T cell proliferation stimulated by plate-bound and soluble anti-CD3 




 T cells were isolated by magnetic cell sorting from the spleens of B10.A 
mice and cultured with isolated microglia, microglia in the presence of astrocytes or 




proliferation determined by CFSE dilution. T cells responded robustly to the anti-CD3 
stimulus (Figure 5.8C). However, when the T cells were stimulated in the presence of 
astrocytes, their proliferation was significantly suppressed. Moreover, in the presence of 
microglia together with astrocytes, that suppression was enhanced. In the presence of 
microglia alone, T cell proliferation was further reduced. This disparity between the 
effect of co-cultured microglia and isolated microglia on T cell proliferation was 
statistically significant. These results were puzzling given the hypothesis that higher 
levels of co-stimulatory molecules should promote T cell activation. In order to 
determine whether secondary signaling was, in fact, leading to a disparity in T 
proliferation, a secondary stimulus was provided exogenously by the inclusion of CD28 
antibody which is expected to ligate T cell CD28 overriding the need for CD80 and 
CD86. Inclusion of this agonist antibody abrogated the suppressive effect of astrocytes. 
While microglia, unlike astrocytes, still suppressed T cell proliferation, the differences in 
microglial environments became inconsequential (Figure 5.8C). This would suggest that 
the difference in the expression of co-stimulatory molecules on microglia in the two 
environments was, indeed, a factor, but it did not explain why lower levels of co-
stimulatory molecules (on co-cultured microglia) lead to increased T cell proliferation.  
This prompted an examination of other possible reasons for this finding. Figure 



























Figure 5.8  Glia affect T cell proliferation. (A) To determine the optimal concentration of the 
agonist anti-CD3, CD4+ T cells were simulated with various concentrations of soluble CD3 
antibody and proliferation assessed by CFSE dilution. CD4+ T cells were magnetically 
isolated from the spleens of B10.A mice. 1X106  CD4+ T cells were loaded with CFSE and 
cultured with increasing concentrations of  CD3 antibody (0.0 - 2.0 µg/ml) for 3 days. T cell 
proliferation was optimal at 1 g/ml.  (B) Both plate-bound (pb) and soluble (sol) anti-CD3 
stimulation leads to efficient CD4+ T cell proliferation. CD4+ T cells were obtained as before 
and 1X106 CD4+ T cells were loaded with CFSE, cultured without exogenous stimulation 
(No αCD3) or with anti-CD3 (1.0 µg/ml) in a plate-bound (αCD3-pb) or soluble (αCD3-sol) 
format. Proliferation was measured after 3 days by assessing CFSE dilution through flow 
cytometry. Numbers above the histogram indicate the percentage of proliferating T cells. 
There was no difference in proliferation, allowing the use of soluble CD3 in subsequent 
studies. (C) In the presence of CD3 alone, both astrocytes and microglia impede T cell 
proliferation. 0.5 X 106 CD4+ T cells were loaded with CFSE and cultured alone (T cell 
alone), in the presence of astrocytes alone (astrocytes), with 50,000 isolated microglia (OFF) 
or with 50,000 microglia in the presence of astrocytes (ON). Astrocytes, isolated microglia 
and microglia in the presence of astrocytes were all previously treated with GM-CSF (25 
ng/ml, 5 days) and LPS (50 ng/ml, 2 days). T cells were stimulated by soluble anti-CD3 (1.0 
µg/ml) alone or anti-CD3 (1.0 µg/ml) together with anti-CD28 (0.5 µg/ml). T cell 
proliferation was assessed by CFSE dilution through flow cytometry after 3 days. Data from 
three independent experiments are expressed as the percentage of T cell proliferation + SEM 
and compared by an ANOVA with a post-hoc Student-Newman-Keul’s test for significance 
at the 95% confidence level. All groups were significantly different from each other in all 
conditions except T cells + astrocytes treated with CD3 and CD28 as well as T cells in the 
presence of microglia + astrocytes treated with CD3 and CD28. Comparison of T cell 
proliferation in the presence of ON and OFF microglia has been performed 9 times with 
















































5.9 Isolated Microglia Promote the Differentiation of Foxp3
+
 T regulatory Cells 
Because the presence of Foxp3
+
 Tregs can suppress T cell proliferation, the presence of 
Foxp3
+
 cells in various culture environments was determined. In a syngeneic 
experimental set-up, CD4
+
 T cells obtained from B10.A mice were cultured with 
enriched astrocytes alone, microglia in the presence of astrocytes and microglia alone. As 
described above, T cells were stimulated at the TCR by soluble anti-CD3. After three 
days in culture, T cells were collected and stained for the Treg transcription factor Foxp3. 
There was no difference in the expression of Foxp3 among groups of T cells cultured 
alone, with addition stimulation by CD28, with astrocytes alone, or with microglia and 
astrocytes (Figure 5.9A). Only T cells plated together with isolated microglia showed a 
significant increase in the percentage of T cells expressing Foxp3.  
In order to determine the role of CD28 in promoting Foxp3 expression, a 
secondary signal was provided by soluble anti-CD28 (0.5 µg/ml). With this treatment, the 
percentage of Foxp3
+
 T cells was significantly reduced in the presence of isolated 
microglia (Figure 5.9B). These data suggest that co-stimulatory signals provided by 
isolated microglial CD80 and CD86 are weak or could be stimulating an inhibitory 
molecule on T cells, such as CTLA-4. This prompted an investigation of a possible role 

































Figure 5.9  Isolated microglia promote the generation of Foxp3
+
 T cells. (A) CD4
+
 T 




 T cells 
were cultured alone (first bar), in the presence of astrocytes alone (Astrocytes), with 
50,000 isolated microglia (OFF) or with 50,000 microglia in the presence of astrocytes 
(ON). Astrocytes, isolated microglia and microglia in the presence of astrocytes were all 
previously treated with GM-CSF (25 ng/ml, 5 days) and LPS (50 ng/ml, 2 days). T cells 
were stimulated by either soluble anti-CD3 antibody (1.0 µg/ml) alone or anti-CD3 
antibody (1.0 µg/ml) and anti-CD28 antibody (0.5µg/ml). After 3 days T cells were 
harvested, fixed/permeabilized and intracellularly stained for Foxp3. Foxp3 expression 
was assessed by flow cytometry. (B) Foxp3 expression was also assessed in CD4
+
 T cells 
stimulated with αCD3 (1.0 µg/ml) and αCD28 (0.5µg/ml) in the presence of astrocytes, 
isolated microglia and in mixed glia. Data in both A and B are expressed as the average 
percentage of Foxp3
+
 T cells + SEM of 3 independent experiments and compared by an 
ANOVA with a post-hoc Student-Newman-Keuls test for significance at the 95% 
confidence level. An asterisk indicates p<0.05 when compared to T cells cultured with 

























































5.10 CD80/CD86 Stimulation of Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) is not 
Responsible for the Increased Percentage of Foxp3
+
 Tregs in the Isolation Cultures 
 
CTLA-4 is an important negative regulator of T cells and is significantly upregulated 
upon T cell activation. By binding CTLA-4, CD80/CD86 can help rein in the immune 
response in part through the generation of Tregs. To determine whether CD80/CD86 
stimulation of CTLA-4 was responsible for the induction of Foxp3
+
 Tregs in the isolated 
microglial cultures, varying doses of CTLA-4 neutralizing antibody were added to the 
cultures and Foxp3 expression assessed. Addition of increasing doses of neutralizing 
CTLA-4 antibodies or its IgG isotype did not affect the percentage of Foxp3
+
 T cells 
produced in the ON or OFF cultures (Figure 5.10). Even high doses of CTLA-4 
neutralizing antibody failed to inhibit the induction of Foxp3
+
 cells, indicating that 
CD80/CD86 stimulation of CTLA-4 stimulation is not responsible for Foxp3 induction.   






































Figure 5.10 Foxp3 induction is not affected by CTLA-4 inhibition. CD4
+
 T cells were 




 T cells were 
cultured with 50,000 isolated microglia (OFF) or with 50,000 microglia in the presence 
of astrocytes (ON). The microglia had been previously treated with GM-CSF (25 ng/ml, 
5 days) and LPS (50 ng/ml, 2 days). T cells were stimulated by soluble anti-CD3 (1.0 
µg/ml) in the presence of increasing amounts of a neutralizing anti-CTLA4 (0.0 – 10 
µg/ml) or its IgG control (5µg/ml). After 3 days T cells were harvested, 
fixed/permeabilized and intracellularly stained for Foxp3. Foxp3 expression was assessed 
by flow cytometry. Data were assessed by regression analysis which rejected the 
hypothesis that there was a dose-response (r = 0.3493). A Student’s t-test determined that 
none of the CTLA-4 antibody treatments differed from the 0 antibody control or from the 













 T-regulatory Cells in the Isolated Microglial Cultures  




 Tregs can affect the immune response by limiting the proliferation of other T-
helper cell subtypes. The data show that T cell proliferation in the isolated microglial 
cultures -- which contain a high percentage of Tregs -- is significantly lower than T cell 
proliferation in the ON cultures. To test the effect of Foxp3
+
 Tregs depletion on T cell 
proliferation, CD4
+
 Tregs were depleted of CD25
+
 cells through magnetic cell sorting and 
cultured alone, with isolated astrocytes, microglia alone or with microglia in the presence 
of astrocyctes. T cells were stimulated with αCD3 (1µg/ml) with or without αCD28 
(0.5µg/ml) and proliferation assessed after 3 days. The differences in proliferation 
between T cells cultured in the presence of ON and OFF microglia disappears in the 
absence of CD25
+
 T cells suggesting that the presence of high numbers of CD25
+
 Tregs 
negatively affects T cell proliferation in the isolated microglial cultures. Figure 5.11 on 
















Figure 5.11 Depletion of CD25
+
 cells rescues CD4 T cell proliferation. CD4
+
 T cells 
were isolated and depleted of CD25
+











 T cells were loaded with CFSE (5µM) and cultured alone, 
with 50,000 isolated microglia (OFF) or with 50,000 microglia in the presence of 
astrocytes (ON). The microglia had been previously treated with GM-CSF (25 ng/ml, 5 
days) and LPS (50 ng/ml, 2 days). T cells were stimulated by soluble anti-CD3 antibody 
(1.0 µg/ml) and anti-CD28 antibody (0.5µg/ml). After 3 days T cells were harvested, and 

























5.12 A Mixed Glial Environment is Less Conducive for Cytokine  
Production by CD4
+
 T cells 
 
T cell-derived cytokines are important mediators of the immune response. To test the 
effect of various culture conditions on the production IFN-γ, IL-17A, IL-10 and IL-4 by 
T cells, supernatants were harvested from T cells activated with αCD3 in the presence of 
isolated microglia, microglia in the presence of astrocytes and astrocytes alone. ELISAs 
reveal that T cells cultured in a mixed glial environment produce significantly lower 
quantities of these cytokines compared to T cells cultured alone or in the presence of 







































Figure 5.12 A mixed glial environment suppresses cytokine production. CD4
+
 T cells 





 T cells were cultured alone, with 50,000 isolated microglia, 50,000 microglia in the 
presence of astrocytes or with astrocytes alone. Astrocytes, isolated microglia and 
microglia in the presence of astrocytes were all previously treated with GM-CSF (25 
ng/ml, 5 days) and LPS (50 ng/ml, 2 days). T cells were stimulated by soluble anti-
CD3antibody (1.0 µg/ml). After 3 days supernatants were harvested and assessed for (A) 
IFN-γ, (B) IL-17A, (C) IL-4 and (D) IL-10 using a sandwich ELISA. The data represent 
triplicates within a single assay and were compared by an ANOVA with a post-hoc 
Student-Newman-Keuls test for significance at the 95% confidence level. Asterisks 
reveal differences between groups. The assay has been done twice with similar results. 








































































































Specific Aim 3: To examine the effects of differences in surface expression of these DC-
specific molecules on T cell proliferation, Foxp3 expression and cytokine production. 
 
Conclusions from specific aim 3: 
 Glia impede T cell proliferation 
 Isolated microglia promote generation of Foxp3+ T cells. CD80/86 interaction 
with CTLA-4 is not the cause of the increased Foxp3
+ 
T cell generation. 
 T cells cultured with microglia in the presence of astrocytes produce significantly 







There are many studies investigating the immune properties of microglia. However, a 
majority of these studies have been conducted on isolated microglia in the absence of 
other cell types – notably astrocytes. Astrocytes play a very important role in maintaining 
CNS homeostasis. In addition to maintaining the blood-brain barrier, they also play a 
vital role in preserving metabolic and biochemical homeostasis. It is not surprising, 
therefore, that they also have a strategic importance in regulating the brain’s immune 
response. One of the ways in which they accomplish this is by assuring that pro-
inflammatory mediators arising from the periphery or from within the CNS are kept 
under tight control. The ability of astrocytes to suppress immune reactions in the CNS is 
one reason why the brain has been labeled “immune privileged.” 
Microglia are considered to be the resident immune cells of the CNS and are 
derived from the same myeloid lineage that also gives rise to a subset of professional 
antigen presenting cells (APCs) of the immune system (Barron, 1995; Chan et al., 2007). 
Microglia themselves are able to become APCs, expressing both MCH Class II as well as 
co-stimulatory molecules necessary for efficient antigen presentation and T cell 
activation. However, microglia do not express these molecules in the healthy CNS 
(Becher et al., 2000b). These studies have found that astrocytes provide a brake on the 
expression of these molecules, and this thesis investigates the mechanism(s) by which 
astrocytes perform this essential homeostatic function. Astrocytic regulation of 





astrocytic-bound molecules have been found to exert their influence on microglial and 
monocyte activation. For instance, astrocyte-derived molecules down-regulate the 
production of IL-12 by microglia activated by IFN-γ/LPS (Aloisi et al., 1997). Though 
this effect on IL-12 production can occur in the presence of astrocyte conditioned 
medium, the effect is more potent when microglia are in contact with the astrocytes. In 
the presence of astrocytes or astrocytic conditioned medium, microglia are markedly less 
neurotoxic even when exposed to beta-amyloid peptide, a potent activator of isolated 
microglia in vitro (von Bernhardi and Eugenin, 2004), and recent bioinformatics studies 
have highlighted the importance of the microenvironment in regulating microglial 
expression of various molecules (Schmid et al., 2009). The results indicate that under 
inflammatory conditions, astrocytes temper the maturation of microglia into functional 
DCs.  
The experiments conducted here show that microglia treated with the DC 
maturation factors GM-CSF and LPS in the presence of astrocytes assume an altered 
phenotype compared to microglia cultured in isolation. Microglia cultured with astrocytes 
are characterized by the reduced expression of the DC marker CD11c and T cell co-
stimulatory molecules. A significantly greater proportion of the isolated microglia 
express CD11c together with co-stimulatory molecules CD40, CD80 or CD86 than 
microglia cultured in the presence of astrocytes. Though there are significant differences 
in the pattern of T cell co-stimulatory molecule expression between the two culture 
conditions, the expression of  MHC class II, a molecule essential for antigen presentation 





To assure that astrocytes were the primary glial components responsible for this 
phenomenon, CD11b
+
 microglia (isolated by magnetic cell sorting) were plated onto an 
enriched bed of confluent astrocytes. When co-cultured in this more homogeneous glial 
environment, microglia still exhibited low surface expression of CD40, thereby 
confirming that the active glial component of co-cultures was, indeed, astrocytes. 
To elicit an adaptive immune response, DCs routinely capture, process and 
present antigens to the appropriate T cells using the MHC class II complex. Engagement 
of the CD3/TCR complex by the MHC class II molecule containing an antigenic peptide 
delivers the primary activation signal to a T cell. Since the data show no significant 
differences in the expression of microglial MHC Class II between the two culture 
conditions, one might be tempted to disregard it as an inconsequential defining factor. 
However, it is important to note that the data only examined the surface expression of 
MHC Class II and not total cellular expression. In addition to the T cell stimulatory 
functions – which occur at the cell membrane – endosomal MHC Class II has also been 
implicated in intracellular signaling events that are distinct from its classical functions. A 
study by Liu and colleagues shows that endosomal MHC Class II molecules – unlike 
their membrane-bound counterparts – can promote TLR-triggered activation/maturation 
of DCs and macrophages by functioning as a scaffolding molecule (Liu et al., 2011). By 
recruiting various downstream members of the TLR signaling pathway and the kinases 
required to activate them (notably the tyrosine kinase Btk), endosomal MHC class II 
substantially enhances the DC response to various TLR ligands. Thus, the production of 
various pro-inflammatory cytokines is significantly attenuated in the absence of 





needs to form a complex with Btk through endosomal CD40 which then interacts with 
other factors to induce efficient TLR signaling.  
Even though isolated microglia express more surface CD40 than do microglia 
cultured with astrocytes, microglia cultured with astrocytes express significantly more 
total CD40 protein as characterized by western blot (Giselles Acevedo, personal 
communication). Moreover, several different isoforms of CD40 can be visualized from 
whole cell lysates derived from microglia cultured in the presence of astrocytes while 
lysates obtained from isolated microglia reveal only a single CD40 isoform. 
Immunocytochemical data also reveal intracellular depots of both CD40 and CD86 
(Jonakait, unpublished observations;   Cruz, unpublished observation).  
Alternative mRNA splicing can generate at least five distinct CD40 isoforms 
(types – I to V) (Tone et al., 2001). Of these five isoforms, only the type-I isoform is able 
to induce intracellular signaling from the cell surface. Though they lack an endodomain 
required for signaling and are thus incapable of traditional signal transduction, types II-
IV are not without function. Type-II-IV isoforms may inhibit CD40 signaling by either 
acting in a dominant-negative fashion at the cell surface (type-III and -IV) or by 
preventing the trafficking of the type-I isoform to the cell surface (type-II). Another 
important intracellular interaction is that described above in which intracellular MHC 
Class II molecules form a complex with CD40 and Btk in endosomes, and intracellular 
CD40 mediates the interaction between MHC Class II and Btk (Liu et al., 2011) thereby 
regulating TLR signaling. This potentially important intracellular interaction, however, 





Microglia respond to LPS by increasing co-stimulatory surface expression, and 
intracellular MHC class II may play a role in facilitiating that signaling (Liu et al., 2011). 
It is reasonable to consider the possibility that the presence of various non-signaling 
isoforms of CD40 in microglia cultured with astrocytes may interfere with TLR signaling 
that is mediated by intracellular MHC class II.  
 RT-PCR analysis of mRNA of MHC class II and the co-stimulatory molecules 
shows that microglia in both conditions upregulate mRNA expression following LPS 
treatment. In all cases, mRNA expression in microglia cultured with astrocytes is 
significantly higher compared to isolated microglia. Analysis of mRNA expression was 
complicated by the lack of suitable internal controls since “housekeeping” genes tested 
(GAPDH, HPRT1 and SDHA) also differed between the two culture conditions (data not 
shown), but repetitive assays were consistent in yielding this phenomenon. This was 
unexpected and seems inconsistent with the analysis of surface protein. The apparent 
inconsistency between message and protein data suggest that the surface expression of 
co-stimulatory molecules might be post-transcriptionally and/or post-translationally 
regulated. Indeed, recent studies have shown that expression of a brain-specific micro-
RNA (miRNA-124) controls activation of peripheral macrophages and microglia 
(Ponomarev et al., 2011).  Subsequent studies from the Jonakait laboratory have shown 
that other miRNAs implicated in controlling macrophage activation are elevated in co-
cultured microglia (Acevedo, personal communication) (Baltimore et al., 2008; Boldin et 
al., 2011; O'Connell et al., 2010). While these data are preliminary, they suggest the 






Other means of regulating surface expression of proteins include alternative 
mRNA splicing and/or trafficking. Recent data from the Jonakait lab have shown that 
CD40 exists in higher quantities and in multiple intracellular isoforms that are only 
present in microglia cultured with astrocytes (Acevedo, personal communication). It is 
thus reasonable to suggest that alternative splicing has created isoforms that lack the 
signal sequence that targets proteins to the membrane. While data are lacking, it is 
possible to hypothesize that CD80 and CD86 are regulated similarly.  
Though microglia are the resident immune cells of the CNS, numerous studies 
utilizing various rodent models for EAE, as well as CNS-specific viral, bacterial and 
parasitic diseases clearly demonstrate that various subsets of peripheral DCs and T cells 
enter the CNS in response to these challenges (Brehin et al., 2008; Fischer et al., 2000; 
Kostulas et al., 2002; Pashenkov et al., 2002). Moreover, MHC class II
+
 peripheral DCs 
have been identified in the choroid plexus, meninges and cerebrospinal fluid (Chinnery et 
al., 2010; Serot et al., 1997). The ability of astrocytes to express immunomodulatory 
capacity against peripherally derived DCs similar to that seen with microglia was 
determined. Consistent with the data of others (Hailer et al., 2001) the data show that 
astrocytes significantly suppress DC maturation of heterogeneous peripheral bone 
marrow-derived precursors. When CD11c
+
 bone marrow-derived cells are purified by 
magnetic cell sorting and cultured on a bed of enriched astrocytes, there is a profound 
reduction in the percentage of cells that express CD40 and CD80 compared to cells 
cultured in isolation suggesting that it is astrocytes and not other hematopoietic cell types 





In addition to suppressing the co-stimulatory molecules and MHC class II, 
astrocytes also prevent the downregulation of the chemokine receptor CX3CR1 in 
microglia in response to GM-CSF and LPS treatment. Data show that the mere removal 
of microglia from an astrocytic environment is enough to cause the downregulation of 
CX3CR1. The ability of astrocytes to prevent the loss of this receptor is important in the 
control of microglial-mediated neural cell death. CX3CR1 has been shown to be 
neuroprotective in various CNS infectious diseases and neurodegeneration models 
(Corona et al., 2010; Jaworski et al., 2011; Suzuki et al., 2011). For instance, Cardona 
and colleagues utilizing these same transgenic mice and various clinically relevant 
models of neurodegeneration show that microglial cells unresponsive to fractalkine are 
significantly more neurotoxic (Cardona et al., 2006). Similarly, Cipriani et al. report that 
CX3CL1 by acting at the microglial CX3CR1 receptor protects against damage caused by 
microglial activation in a permanent middle cerebral artery occlusion (pMCAO) model 
(Cipriani et al., 2011).  
Given the data obtained from the transgenic CX3CR1
GFP/GFP 
mice, the expression 
of endogenous CX3CR1 receptor in wildtype microglia was assessed. A flow cytometric 
analysis of the CX3CR1 receptor in WT C57BL6/J isolated microglia treated with GM-
CSF and LPS revealed that approximately 50% of the microglia still retained the receptor 
(data not shown). This was surprising since none of the transgenic microglia retain their 
GFP expression in the absence of astrocytes. Moreover, since GFP is under the direct 
control of the CX3CR1 promoter, one would expect the presence or absence of GFP in 
the transgenic microglia to correlate directly with the presence or absence of the 





Though the discrepancies between the transgenic and wild-type data are 
admittedly troubling, the transgenic data might prove to be useful and may yet shed light 
on how CX3CR1 expression is regulated by astrocytes. For instance, data reveal that a 
large portion of isolated GFP-microglia retain their GFP expression when cultured with 
GM-CSF and LPS in the presence of Matrigel
TM
 even in the absence of astrocytes. 
Furthermore, a sizeable percentage of isolated GFP microglia devoid of GFP expression 
regain GFP expression after being placed into an astrocytic environment indicating that 
contact with the astrocytic environment has initiated de novo transcription and translation 
of the CX3CR1
GFP/GFP
 in the transgenic microglia. These data suggest that extrinsic cues 
provided by the astrocytic environment may somehow affect the transcription, translation 
and/or the stability of the CX3CR1.                
   Taken together, the above data demonstrate that an astrocytic environment not 
only prevents the efficient maturation of microglia and BM precursors into efficient DCs 
but it may also enhance neuroprotection by preserving microglial expression of the 
fractalkine receptor. 
Since astrocytes are capable of secreting a wide variety of pro- and anti-
inflammatory immune cytokines, the effects of endogenous and exogenous PGE2, IL-10 
and TGF-β on microglial maturation in the presence or absence of astrocytes was 
investigated. As described above (see Background), numerous studies have shown these 
cytokines to broadly suppress isolated microglial activation in response to inflammatory 
stimuli. In agreement with other studies, addition of PGE2 suppressed the expression of 
co-stimulatory molecules in isolated microglia. Intriguingly, PGE2 had the opposite 





totally unexpected;   others have also shown that PGE2 can be pro-inflammatory under 
certain conditions (Sheibanie et al., 2007).  
Analysis of IL-10 expression through an ELISA revealed that the production of 
IL-10 in both culture conditions increased in a time-dependent manner. However, the 
amount of IL-10 in the mixed glial culture was significantly higher when compared to 
that in the isolated microglial cultures. Furthermore, unlike isolated microglial cultures, 
IL-10 was present consistently throughout the entire duration of LPS treatment in the 
mixed glial cultures. Given the elevated concentrations of endogenous IL-10, it is perhaps 
not surprising that the addition of exogenous IL-10 had no discernible effect. However, 
given the anti-inflammatory role of IL-10 on microglial activation, neutralizing IL-10 
was expected to reverse the suppression of microglial activation. ELISA data showed that 
the addition of the antibody successfully neutralized IL-10 (data not shown). Even so, it 
had no significant effect in either culture condition ruling out IL-10 as the mediator of 
glial inhibition of the DC phenotype.  
In addition to PGE2 and IL-10, the role of TGF-β1 was tested. TGF-β1 has been 
shown by others to mediate astrocytic neuroprotection (Dhandapani et al., 2003), to 
down-regulate activation of invading macrophages (Hailer et al., 1998) and microglia 
(Kim et al., 2004; Ledeboer et al., 2000; Suzumura et al., 1993), and promote an 
immature DC-like phenotype in isolated microglia (Xiao et al., 2002). The addition of 





 microglia, suggesting a possible role in mediating the DC inhibition. In 
order to determine whether endogenous TGF-β was indeed responsible, the endogenous 










 microglia in mixed glial cultures. The apparent 
contradiction that both the addition and the neutralization of TGF-  had the same action 
might be explained by the fact that the antibody neutralized all three isoforms of TGF-
which might have contradictory effects. The consequences of adding exogenous TGF-
2 and 3 was not pursued.  
Because the three mediators examined did not appear to be the relevant 
candidates, a Transwell
TM
 system was employed to examine the possibility that other 
astrocyte-derived soluble molecules were involved. CX3CR1
GFP/GFP
-expressing microglia 
were used in initial studies because the down-regulation of CX3CR1 in some conditions 
is inhibited by soluble factors such as IL-10 and IFN-γ (Ramos et al., 2010). Separation 
of microglia from a confluent bed of astrocytes failed to maintain GFP expression.  The 
expression of CX3CR1 was maintained only when microglia were in direct contact with 
astrocytes thereby eliminating most soluble factors as mediators.  
Similar results for CD40 were obtained when isolated microglia were cultured in 
the Transwell™ setting. The percentage of cells expressing CD11c and CD40 is the same 
in microglia grown apart from astrocytes and those cultured in a Transwell
TM
 system. 
These data conclusively show the need for contact between microglia and astrocytes in 
order for the latter to inhibit the maturation of the former.  
These data, however, do not eliminate all soluble factors as potential astrocyte-
derived mediators. One such factor that warrants further investigation is 
thromobospondin (TSP). Though TSP is a soluble factor, it can function as a “bridging” 





(Brown and Frazier, 2001; Gao et al., 1996). TSP exerts its functions over distances that 
are much smaller than a Transwell
TM
 apparatus allows. The anti-inflammatory properties 
of TSP are well characterized. Treatment of DCs with TSP-1 reduces the expression of 
molecules required for T cell stimulation (Doyen et al., 2003; Mittal et al., 2010). TSP-1 
also decreases the production of inflammatory cytokines by PBMCs (Demeure et al., 
2000). Furthermore, TSP-1 ligation of CD47 on T cells induces their differentiation into 
Foxp3
+
 Tregs in response to inflammatory signals (Grimbert et al., 2006). And 
importantly,  astrocytes produce copious amounts of TSP-1 (Lanz et al., 2010).  TSP has 
some unique properties that make it a candidate for consideration as an astrocytically-
derived molecule that can affect microglial function. TSP-1 has a heparin binding domain 
(HBD) at its N-terminus and a C-terminal cell binding domain (CBD) (Krispin et al., 
2006). These two domains can affect cells differently based on the specific receptors 
expressed by the cells. For instance, TSP-1 HBD when bound to DCs induces a 
phagocytic state whereas CBD binding induced a tolerizing phenotype (Tabib et al., 
2009). Future studies should consider TSP as a possible astrocytic mediator of DC 
inhibition. 
Other molecules within the astrocytic environment may be important. ECM 
molecules such as fibronectin and laminin secreted by astrocytes may negatively affect 
microglial maturation. Components of the ECM are known to suppress the induction of 
microglial iNOS/NO in response to LPS stimulation (Kim et al., 2006). Furthermore, in 
the presence of laminin or fibronectin, human DCs tend to maintain a “more immature” 





molecules (Garcia-Nieto et al., 2010). However, these same DCs were capable of 
efficient T cell stimulation upon their removal from the inhibitory ECM proteins.  
The data presented here show that microglia are being similarly affected. 
Microglia treated with GM-CSF and LPS on Matrigel
TM
 reveal a percentage of cells 
expressing CD11c and CD40 that is similar to that of isolated microglia. However, the 
MFI of CD40 is lower, reminiscent of the effect provided by an astrocytic environment. 
Similarly, CX3CR1
GFP/GFP
 microglia retain their GFP expression to a large extent in the 
presence of Matrigel
TM
. These data add support to the hypothesis that astrocyte-derived 
ECM proteins affect microglial maturation.  
Though microglia cultured on Matrigel
TM
 seem to mimic the phenotype of 
microglia grown in the presence of astrocytes, the data show that the components of 
Matrigel
TM
 are not entirely sufficient to replicate the action of astrocytes. This implies 
that there might be other astrocytic factor(s) that also play a role in modulating microglial 
behavior. These factors could be molecules like thrombospondin that require membrane 
associated proteins for their effect and/or astrocytic membrane-bound molecules that 
microglia are required to touch and/or ECM constituents.  
The phenotype expressed by DCs significantly affects their capacity to stimulate 
the activation and proliferation of T cells. Owing to their immature DC phenotype, 
microglia in the presence of astrocytes might be expected to be inefficient T cell 
stimulators.  To test this hypothesis, T cells were cultured with microglia alone, 
astrocytes alone or microglia in the presence of astrocytes. CD4
+
 T cells were stimulated 





whereas microglial CD40, CD80 or CD86 stimulating their appropriate cognate ligand 
would theoretically provide the T cells with the secondary signal.  
Compared to T cells cultured alone, the data show that a glial environment 
significantly impedes T cell proliferation. Though microglia in the presence of astrocytes 
were more effective in stimulating T cell proliferation than isolated microglia, T cell 
proliferation was significantly lower in both culture conditions when compared to T cells 
cultured alone or in the presence of an enriched astrocytic culture.  
A different result is obtained if an exogenous stimulator for signal two is 
provided. The inclusion of an agonist CD28 antibody together with anti CD3 eliminates 
the differences between the proliferation of T cells cultured alone and with astrocytes 
alone. Moreover, the difference between the proliferation of T cells cultured with isolated 
and co-cultured microglia disappears. What remains, however, is the suppression of 
proliferation whenever microglia are present. Since T cells cultured in these conditions 
do not proliferate as much as those cultured alone or cultured with astrocytes alone, this 
suggests that microglia irrespective of their environment suppress T cell proliferation.  
The inhibitory effect of astrocytes on T cell proliferation in the presence of anti-
CD3 is unexplained, but could be the result of an unknown ligand from astrocytes 
interacting with inhibitory molecules on the T cell surface. The addition of activated 
microglia to the astrocytic environment is even less conducive to T cell proliferation. 
However, because isolated microglia (with their full complement of co-stimulatory 
molecules) are less effective than co-cultured microglia (with their immature complement 
of co-stimulatory molecules) in promoting T cell proliferation, molecules other than the 





CTLA-4 following T cell activation (Walunas et al., 1994) may allow for its ligands 
CD80 and CD86 to have an inhibitory effect on T cell activation and cell cycle 
progression. Moreover, CTLA-4 has additional binding partners that include B7-H2  
which can bind CD28, thereby activating T cells. With an upregulation of CTLA-4, 
however, B7-H2 is prevented from activating CD28.  B7-H2 expression on astrocytes and 
microglia has not been examined.  
PD-L1 and PD-L2, present on astrocytes and microglia, are upregulated by pro-
inflammatory signals (Pittet et al., 2011). Ligation of PD-1 on T cells inhibits PI3 kinase 
activity and lowers T cell proliferation (Sandner et al., 2005). Moreover, PD-1 mediated 
inhibition correlates with the strength of TCR ligation (Freeman et al., 2000). While both 
plate-bound and soluble anti-CD3 were equally efficacious in promoting T cell 
proliferation, there is no information on that strength relative to an in vivo stimulation. 
Importantly, PD-1 inhibition can be overcome by strong stimulation of CD28 (Freeman 
et al., 2000). If PD-L1 or PD-L2 were expressed on either microglia or astrocytes, this 
could account for their suppressive effects on T cell proliferation and explain why such 
suppression was overcome by the addition of anti-CD28. 
An additional candidate for T cell inhibition is B7-H3, a newly-identified member 
of the B7 family of co-stimulatory molecules. A B7-H3 agonist fusion protein inhibits 
murine T cell proliferation generated by anti-CD3 (Leitner et al., 2009; Prasad et al., 






An important future direction of these studies would be an investigation of these 
inhibitory co-stimulatory molecules on isolated and co-cultured microglia to determine 
whether they may be players in the inhibition of T cell proliferation observed here. 
The ability of the two culture conditions to induce Foxp3
+
 T cells was assessed. 
Foxp3
+
 T cells are a subtype of T-helper cells that exhibit anti-inflammatory properties 
and have the capacity to downregulate the immune response. Studies show that Foxp3
+
 T 
cell generation can be affected by the strength and timing of the primary and secondary 
signaling provided by DCs. Since microglia in the presence of astrocytes express lower 
amounts of the co-stimulatory CD40, CD80 and CD86 molecules one should expect a 
higher percentage of Foxp3
+
 T cells in these cultures. However, the data show that the 
opposite is true, i.e., a significantly higher percentage of T cells harvested from isolated 
microglial cultures are Foxp3 positive compared to those isolated from the mixed glial 
environment. Two possible explanations can be invoked to account for this discrepancy. 
The higher percentage of Foxp3
+
 cells in the isolated microglial cultures could be the 
result of proliferation of endogenous Foxp3
+
 cells or it could be due to the de novo 





 T cells used in the experiments were obtained through magnetic cell 
sorting from the spleens of B10.A mice. Without further purification steps, isolating T 
cells in this manner results in a heterogeneous mix of various CD4
+
 T helper subtypes 
including naïve (Th0), Th1, Th2, Th17 and Foxp3
+
 Tregs. Data from the Jonakait lab (not 
shown) and others indicate that Foxp3
+
 cells may comprise 5-10% of the CD4
+
 T cell 





microglia could result from preferential proliferation of this endogenous population of 
Foxp3
+
 T cells or from the de novo induction of Foxp3
 
in Th0 cells.  
While the here experiments did not distinguish between these possibilities,  others 
have shown that a strong CD28 signal even in the presence of a weak TCR signal 
promotes proliferation of Foxp3
+
 Tregs (Hombach et al., 2007).  Similarly, such disparity 
in signaling also promotes de novo expression of Foxp3  (Gabrysova et al., 2011; 
Molinero et al., 2011). In the experiments here, T cells were stimulated with soluble anti-
CD3 antibody. However, anti-CD3 antibody was used in a soluble form instead of the 
more conventional plate-bound antibody. A plate-bound antibody is deemed to provide T 
cells with a “stronger” primary signal than a soluble antibody. One reason for this is that 
the plate-bound antibody is more likely to cross-link the various signaling proteins than 
an antibody in solution. A weak primary signal coupled with the relatively stronger 
secondary signal provided by the isolated microglia may explain the higher percentage of 
Foxp3
+
 cells there. Given the disparity of the signaling strengths provided here, it is 
likely that the increased presence of Tregs is due to both induction and proliferation. 
The addition of exogenous anti-CD28 did not change the percentage of Foxp3
+
 
cells in T cells cultured alone or in the presence of co-cultured microglia. However, it did 
lower significantly the percentage of Fox3-expressing cells in the presence of isolated 
microglia. This may be due to an increased proliferation of other T cell types relative to 
Tregs. This would tend to lower the percentage of any single population. On the other 
hand, one report shows that the addition of soluble anti-CD28 in a pro-inflammatory 
environment lowers the percentage of Foxp3-expressing cells (Bouguermouh et al., 





assuredly pro-inflammatory (see Figure 5.12). These data together confirm 1) the 
importance of the strength and timing of co-stimulatory signals and 2) the importance of 
astrocytes in regulating the microglia response. 
An experiment using an antigen-dependent T cell stimulation protocol is an 
important future direction. In such an experiment microglia would have to phagocytose, 
process and present an antigen to a CD4
+
 T cell in an MHC class II context. Since this 
experiment would examine all the important functional aspects of a microglial-DC, it 
would provide a more complete picture of how isolated microglial behavior differs from 
microglia in an astrocytic environment.  
Another consideration for Foxp3 induction is the effect of negative stimulation by  
CD80/86 of CTLA-4. By inducing apoptosis or anti-inflammatory properties in the target 
cells, negative stimulation of T cells by CD80 and CD86 can terminate the immune 
response at the appropriate time. Studies show that CD80 and CD86 bind CTLA-4 
preferentially and with much greater affinity than CD28. Moreover, CD80/86 binding of 
CTLA-4 tends to elicit anti-inflammatory responses  (Vandenborre et al., 1999; Walunas 
et al., 1994; Wells et al., 2001). One way this is accomplished is through the production 
of Foxp3
+
 Tregs. CD80/CD86 stimulation of CTLA-4 under certain conditions can lead to 
the induction of Foxp3 in T cells (Pletinckx et al., 2011). Since a significantly greater 
percentage of isolated microglia express CD80 and CD86, it was reasonable to 
hypothesize that CD80/CD86 stimulation of CTLA-4 might be the reason for the 
increased number of Foxp3
+
 T cells. A neutralizing antibody against CTLA-4 was used to 
test this hypothesis. Blocking CTLA-4 interaction with CD80/86 was expected to reduce 
the observed percentage of Foxp3
+
 cells. However, Foxp3
+ 





unaffected even in the presence of the neutralizing antibody suggesting that CD80/86 
stimulation of CTLA-4 is probably not the cause of the increase in Foxp3 cell numbers. 
Furthermore, the elimination of CTLA-4 as a mechanism for Foxp3 generation lends 
more support to the suggestion that weak TCR signaling coupled with strong co-
stimulatory signaling might be the cause of Foxp3 induction in the isolated microglial 
cultures.  
In addition to suppressing T cell proliferation, the stimuli arising from the glial 
environment also seem to inhibit the efficient secretion of various cytokines by T cells. 
The pro- or anti-inflammatory activity of T cells is determined in part by the type of 
cytokines they produce. An analysis of the supernatants by ELISAs reveals that a mixed 
glial environment hinders the secretion of cytokines by the T cells whereas, isolated 
microglia promote both pro- and anti-inflammatory cytokine secretion by T cells. The 
production of pro-inflammatory IFN-γ, IL-17A and anti-inflammatory IL-10 and IL-4 is 
significantly reduced in T cells cultured in a mixed glial environment. Though a greater 
percentage of T cells cultured with isolated microglia assume a Foxp3
+
 Treg phenotype, 
these cultures tended to produce significantly more IL-17A and IFN-γ two pro-
inflammatory cytokines implicated in auto-immune disorders.  
The cytokine milieu generated in the various culture conditions is likely due to the 
variability of the co-stimulatory signaling. The engagement of co-stimulatory molecules 
on DCs by their cognate ligands on naïve or differentiated T cells can modify the 
phenotype of the DCs themselves. For instance, the engagement of CD40 by CD40L (on  
T cells) is sufficient to induce the maturation of immature DCs in certain instances (Fujii 





significantly increase their production of IL-23, a cytokine essential for Th17 
differentiation (Sender et al., 2010) revealing the importance of the crosstalk between 
DCs and T cells.  The differentiation of Th17 cells also requires IL-6 and TGF-β. High 
levels of IL-6 were observed in both culture conditions, and it increases over time (data 
not shown). The presence or absence of TGF-β in the culture system was not assessed but 
presumably the TGF-β already present in serum is enough to drive Th17 generation. In 
light of this study and data showing the very high expression of surface CD40 in isolated 
microglia and the detection of high quantities of IL-17 in the supernatants, it is quite 
feasible that the mechanism put forth by Sender et al. is also at work in this study.  
The production of an appropriate T cell response is of vital importance to the 
healthy brain, and the data indicate that an astrocytic environment plays an important role 
in maintaining brain homeostasis. This level of immunosuppression is generally thought 
to be beneficial. However, the interaction between becomes detrimental when that 
immunosuppression occurs within tumors. Tumors including gliomas tend to induce an 
anti-inflammatory environment as well as the formation of Foxp3
+
 Tregs which 
compromise the immune response and contribute to the immune evasion of the tumor and 
poor prognosis (Hussain et al., 2006; Wei et al., 2010)  While they contain resident 
microglia and even peripheral DCs, these are characterized by low expression of MHC 
class II, CD40 and CD86 and are unable to mount an appropriate immune response. Their 
immaturity with respect to antigen-presentation may contribute to an environment in 
which anti-inflammatory Foxp3
+
 Tregs are generated (Kostianovsky et al., 2008). Indeed 
the conversion to a more mature phenotype markedly reduces the immunosuppressive 





introduction of mature DCs pulsed with tumor antigens (Pellegatta et al., 2010). A recent 
paper of interest suggests that the introduction of gliomas into the CNS does not elicit an 
immune response, whereas implantation into the periphery does suggesting the profound 
immunosuppression elicited in a brain microenvironment (Biollaz et al., 2009). 
Likewise, it appears that the depletion of endogenous Foxp3
+
 Treg may also 
provide protection against gliomas by unleashing the latent potential of the hitherto 
suppressed immune system (Maes et al., 2009). The same study shows that the prognosis 
gets even better when Tregs ablation is coupled with the introduction of mature DCs 
pulsed with tumor antigens. This suggests that maximal immune response can only be 
achieved in the absence of Treg mediated suppression as well as the presence of DCs in a 
proper state of maturation.  
The data in this thesis show that microglia in the presence of astrocytes are 
characterized by their low expression of CD80, CD86 and MHC class II as well as their 
reduced capacity to stimulate T cell activation and proliferation when compared to T cells 
cultured alone. It is appears that the mechanisms that prevent an overblown T cell 
response in the healthy CNS are co-opted and exaggerated by tumor cells to their own 
advantage. Understanding the mechanism(s) through which this occurs in the healthy 
CNS may shed further light on how tumors evade immune surveillance.  
In contrast to their detrimental role in the pathogenesis of gliomas, activation of 
microglia and CNS DCs has been shown to exert a neuroprotective effect. Spinal cord 
injury (SCI) studies indicate that the presence of activated microglia and/or mononuclear 
cells at the site of injury can be directly correlated with morphological and functional 





basic protein either directly into the site of the wound or in the peritoneum after the SCI 
lead to significant improvements in recovery (Hauben et al., 2003; Liu et al., 2009). 
Moreover, this recovery is contingent on the presence of mature T cells since the 
depletion T cells results in negligible improvement after SCI. In addition to recruiting T 
cells, activated DCs and microglia aided recovery by reducing the formation of glial scars 
that impede neuroregeneration (Hauben et al., 2003).  
Glias scars comprise a heterogeneous mixture of cells including microglia, 
reactive astrocytes and CNS invading DCs. They produce high quantities of  extracellular 
matrix molecules including chondroitin sulfate proteoglycans (CSPG) and laminin 
(Katoh-Semba et al., 1995). The data here and that of others suggest that ECM molecules 
or their degradation products have an anti-inflammatory effect on microglia (Ebert et al., 
2008; Rolls et al., 2004). While protecting against neuronal death, this down-regulation 
can also prevent the elimination of the glial scar either by microglial phagocytosis or T 
cell invasion.  
Conclusions 
The data presented here and that of others suggest that microglia are tightly controlled by 
an astrocytic environment that prevents when possible the over activation of microglia. 
This is neuroprotective in some instances where pro-inflammatory events could cause 
neuronal cell death or promote autoimmunity. But this inhibitory effect has a darker side. 
Microglial inflammation can be beneficial both in recovery from traumatic injury and is 
essential for an effective response against brain tumors. Understanding the mechanism(s) 





for proper therapeutic intervention. The data point to the complex astrocytic 
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